Arvinas is a biopharmaceutical company focused on developing targeted protein degradation therapeutics to treat various diseases.

Arvinas is a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. Arvinas uses its proprietary PROTAC Discovery Engine platform to engineer proteolysis targeting chimeras, or PROTAC targeted protein degraders, that are designed to harness the body’s own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. In addition to its robust preclinical pipeline of PROTAC protein degraders against validated and “undruggable” targets, the company has three investigational clinical-stage programs currently enrolling: &nbsp;ARV-102 for the treatment of patients with neurodegenerative disorders,ARV-393 for the treatment of patients with relapsed/refractory non-Hodgkin Lymphoma and potentially other lymphomas, and ARV-806, a KRAS G12D PROTAC for the treatment patients with solid tumors with KRAS G12D mutations. &nbsp; On August 8th 2025, the U.S. Food and Drug Administration (FDA) &nbsp;accepted the New Drug Application (NDA) for vepdegestrant- an investigational, orally bioavailable PROTAC estrogen receptor degrader- for its use as a monotherapy in the treatment of adults with estrogen receptor–positive (ER+), human epidermal growth factor receptor 2–negative (HER2-), ESR1-mutated advanced or metastatic breast cancer previously treated with endocrine-based therapy. In September 2025, Arvinas and Pfizer announced their plan to jointly select a third party for the out-licensing and commercialization of vepdegestrant. &nbsp; In April 2024, Arvinas entered into a transaction with Novartis, including a global license agreement for the development and commercialization of the clinical stage PROTAC&nbsp;androgen receptor protein degrader ARV-766 for the treatment of prostate cancer. The transaction closed in May 2024. #TeamArvinas is made up of passionate and curious employees, whose diverse thoughts and perspectives are highly valued. Arvinas employees embrace the freedom to pursue innovation, think creatively, and give back. They are driven by the company’s values and mission – to improve the lives of patients with serious diseases by pioneering therapies created with our revolutionary PROTAC protein degradation platform. We’re really excited about the work we’re doing inside and outside of Arvinas, and think you will be, too. But don’t just take our word for it – learn more about life at Arvinas and what employees have to say. &nbsp; For more information, please visit www.arvinas.com.&nbsp; Position Summary Our Bioinformatics and Proteomics team is looking for a highly motivated individual to explore tools and approaches to optimize computational processes. There may be additional opportunities to aid in application development to allow the team to leverage both internal and external data to support our drug development programs. The intern will present results at team meetings and will summarize their work as a talk or poster at Arvinas at the conclusion of the internship. This position reports to the Senior Research Investigator, Bioinformatics and can be located remotely within the U.S. &nbsp; Principal Responsibilities Key responsibilities of this role include, but are not limited to: Help identify and process high dimensional data sets for analysis Utilize state of the art tools to help optimize code, workflows, or applications to analyze and visualize biological data Prepare and present results at an internal Arvinas function at the conclusion of the internship. &nbsp; Qualifications Proficiency in Python and/or R programming required; experience with Linux and AWS is a plus Knowledge and experience with data analysis &amp; visualization, modeling, and machine learning methods and tools Knowledge and experience with AI tools for code and process optimization Experience working on neurobiology or cancer biology projects is desirable. Must be able to work effectively in both independent and team contexts. Arvinas will not be providing VISA sponsorship for this position now or in the future. You must have the ability to work without a need for current or future VISA sponsorship. The duties of this role are generally conducted in a combination of company office and home office environments. Employees must be able, with or without an accommodation to lift/carry 15/30 pounds unassisted/assisted; work comfortable in a controlled environment with and around biological, infectious and hazardous materials; gown/degown PPE; use a computer; engage in communications via phone, video, and electronic messaging; engage in problem solving, analysis and dialogue; collaborate with others; maintain general availability during standard business hours. &nbsp; EDUCATION Computational Biology, Bioinformatics, Computer Science&nbsp;or related&nbsp;major; candidates should be at least a rising junior/senior undergraduate or&nbsp;Master’s&nbsp;program student&nbsp; Completed coursework related to neuroscience or cancer biology preferred &nbsp; Arvinas is proud to offer a competitive package of base and incentive compensation as well as a comprehensive benefits program designed to support the health, wellness and financial security of our employees and their families. Benefits include group medical, vision and dental coverage, group and supplemental life insurance, and much more. To learn more about Arvinas, please visit www.arvinas.com Arvinas is an equal opportunity employer. All qualified applicants will be considered for employment without regard to race, color, religion, sex, sexual orientation, gender identify, national origin, disability or protected veteran status.&nbsp; &nbsp;

Summer intern - Bioinformatics and Proteomics

Arvinas is a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. Arvinas uses its proprietary PROTAC Discovery Engine platform to engineer proteolysis targeting chimeras, or PROTAC targeted protein degraders, that are designed to harness the body’s own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. In addition to its robust preclinical pipeline of PROTAC protein degraders against validated and “undruggable” targets, the company has three investigational clinical-stage programs currently enrolling: &nbsp;ARV-102 for the treatment of patients with neurodegenerative disorders,ARV-393 for the treatment of patients with relapsed/refractory non-Hodgkin Lymphoma and potentially other lymphomas, and ARV-806, a KRAS G12D PROTAC for the treatment patients with solid tumors with KRAS G12D mutations. &nbsp; On August 8th 2025, the U.S. Food and Drug Administration (FDA) &nbsp;accepted the New Drug Application (NDA) for vepdegestrant- an investigational, orally bioavailable PROTAC estrogen receptor degrader- for its use as a monotherapy in the treatment of adults with estrogen receptor–positive (ER+), human epidermal growth factor receptor 2–negative (HER2-), ESR1-mutated advanced or metastatic breast cancer previously treated with endocrine-based therapy. In September 2025, Arvinas and Pfizer announced their plan to jointly select a third party for the out-licensing and commercialization of vepdegestrant. &nbsp; In April 2024, Arvinas entered into a transaction with Novartis, including a global license agreement for the development and commercialization of the clinical stage PROTAC&nbsp;androgen receptor protein degrader ARV-766 for the treatment of prostate cancer. The transaction closed in May 2024. #TeamArvinas is made up of passionate and curious employees, whose diverse thoughts and perspectives are highly valued. Arvinas employees embrace the freedom to pursue innovation, think creatively, and give back. They are driven by the company’s values and mission – to improve the lives of patients with serious diseases by pioneering therapies created with our revolutionary PROTAC protein degradation platform. We’re really excited about the work we’re doing inside and outside of Arvinas, and think you will be, too. But don’t just take our word for it – learn more about life at Arvinas and what employees have to say. &nbsp; For more information, please visit www.arvinas.com.&nbsp; Senior Director, External API Manufacturing and Supply Position Summary We are currently seeking an experienced and strategic individual to join the Technical Operations manufacturing and supply team at Arvinas. The Sr. Director will serve as a core member of a multidisciplinary project team and directly impact strategy, timing, and execution of both drug substance development and manufacturing.&nbsp; A key responsibility of this role will be technical oversight of the associated CDMOs.&nbsp; The qualified individual will have a track record of accomplishment in preparing RFPs, CDMO selection, contracting, and CDMO oversight.&nbsp;&nbsp; This position reports to our Executive Director, External API Manufacturing and Supply and will work closely with the members of Chemical Process R&amp;D.&nbsp; In addition, the Sr, Director will work closely with project teams to develop and execute a streamlined program to advance assets into clinic and then into commercialization. The incumbent will ensure all activities occur in compliance with the appropriate SOPs and regulations.&nbsp; This position reports to the Executive Director, External API Manufacturing and Supply and will be located at our headquarters in New Haven, CT or can be performed from a remote location within the U.S. &nbsp; Principal Responsibilities Key responsibilities of this role include, but are not limited to: Design and implement a comprehensive API supply chain strategy for specific projects at Arvinas. Working with Process R&amp;D, craft and distribute request-for-proposals to CDMOs to access intermediates and API supplies to enable the Arvinas pipeline. Evaluate proposals and quotes matching the capabilities of the supplier with the project requirements in terms of quantity, quality, and timing of deliverables. Working with Process R&amp;D select the best providers of service to meet project needs. Working with internal and external legal resources craft master service agreements and contracts to reflect required deliverables. As the primary contact with the contractors, manage day-today interactions to ensure that deliverables are completed as contracted. Contribute to technical oversight of contracted suppliers in execution of API-related deliverables. Drive forecast planning and inventory management of project intermediates and APIs to meet near-term and long-term goals. Incorporate risk-mitigation strategies. Participate in budget-planning for API campaigns and track all spend relative to budget. Communicate production schedules to Project Management and the project team as part of project Integrated Development Plans for specific Arvinas assets. Manage the CMC API Supply Chain interfaces with Drug Product Supply, Quality Assurance, and Regulatory Compliance. Establish detailed plans to guide project chemical development activities from early development to commercialization, ensuring all quality and regulatory requirements are proactively satisfied. Participate in strategy discussions to ensure that decisions align with agreed upon business direction and processes. Lead the collection of relevant data and reports from suppliers and contribute to drafting of INDs, NDAs, and associated amendments. &nbsp; &nbsp; Qualifications A successful history of hands-on chemical development and scale-up. A successful track record in the RFP/contracting process along with detailed technical oversight of third-party contractors. Experience with management of all stages of API development and manufacturing. Comprehensive working knowledge of Good Manufacturing Practices (cGMPs) and regulatory guidance documents as they relate to manufacture and quality testing of pharmaceutical products. Demonstrated experience in inventory management and forecasting. Ability to effectively prioritize and deliver on tight timelines. Outstanding problem-solving abilities. Detail-oriented, with good organizational and project management skills Good oral and written communications skills. Proficient with MS Word, PowerPoint, Excel. Strong leadership, project planning, negotiation and presentation skills. Significant experience in communicating/presenting complex information to senior management and regulatory agencies. Ability to multi-task and manage several projects in parallel, paying attention to detail. Ability to forge cross-functional working relationships with internal and external project partners. Ability to be proactive in identifying issues and hurdles that may hinder the effective progression of an asset and resolve the issues in a timely and creative fashion. Must be legally authorized to work in the US without the need for employer sponsorship now or at any time in the future. The duties of this role are generally conducted in a combination of office, lab and home office environments. Employees must be able, with or without an accommodation to lift/carry 15/30 pounds unassisted/assisted; work comfortable in a controlled environment with and around biological, infectious and hazardous materials; gown/degown PPE; use a computer; engage in communications via phone, video, and electronic messaging; engage in problem solving, analysis and dialogue; collaborate with others; maintain general availability during standard business hours. Education An MS/Ph.D in Chemistry or Chemical Engineering or related technical field and 15+ years relevant experience in CMC operational roles, preferably in a bio-tech environment. &nbsp; Arvinas is proud to offer a competitive package of base and incentive compensation as well as a comprehensive benefits program designed to support the health, wellness and financial security of our employees and their families. Benefits include group medical, vision and dental coverage, group and supplemental life insurance, and much more. To learn more about Arvinas, please visit&nbsp;www.arvinas.com Arvinas is an equal opportunity employer. All qualified applicants will be considered for employment without regard to race, color, religion, sex, sexual orientation, gender identify, national origin, disability or protected veteran status.&nbsp; &nbsp;

Senior Director, External API Manufacturing and Supply

Arvinas is a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. Arvinas uses its proprietary PROTAC Discovery Engine platform to engineer proteolysis targeting chimeras, or PROTAC targeted protein degraders, that are designed to harness the body’s own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. In addition to its robust preclinical pipeline of PROTAC protein degraders against validated and “undruggable” targets, the company has three investigational clinical-stage programs currently enrolling: &nbsp;ARV-102 for the treatment of patients with neurodegenerative disorders,ARV-393 for the treatment of patients with relapsed/refractory non-Hodgkin Lymphoma and potentially other lymphomas, and ARV-806, a KRAS G12D PROTAC for the treatment patients with solid tumors with KRAS G12D mutations. &nbsp; On August 8th 2025, the U.S. Food and Drug Administration (FDA) &nbsp;accepted the New Drug Application (NDA) for vepdegestrant- an investigational, orally bioavailable PROTAC estrogen receptor degrader- for its use as a monotherapy in the treatment of adults with estrogen receptor–positive (ER+), human epidermal growth factor receptor 2–negative (HER2-), ESR1-mutated advanced or metastatic breast cancer previously treated with endocrine-based therapy. In September 2025, Arvinas and Pfizer announced their plan to jointly select a third party for the out-licensing and commercialization of vepdegestrant. &nbsp; In April 2024, Arvinas entered into a transaction with Novartis, including a global license agreement for the development and commercialization of the clinical stage PROTAC&nbsp;androgen receptor protein degrader ARV-766 for the treatment of prostate cancer. The transaction closed in May 2024. #TeamArvinas is made up of passionate and curious employees, whose diverse thoughts and perspectives are highly valued. Arvinas employees embrace the freedom to pursue innovation, think creatively, and give back. They are driven by the company’s values and mission – to improve the lives of patients with serious diseases by pioneering therapies created with our revolutionary PROTAC protein degradation platform. We’re really excited about the work we’re doing inside and outside of Arvinas, and think you will be, too. But don’t just take our word for it – learn more about life at Arvinas and what employees have to say. &nbsp; For more information, please visit www.arvinas.com.&nbsp; &nbsp; Position Summary&nbsp; We are looking for a highly motivated individual to work as a summer intern from May to Aug 2026. The incumbent will be trained and mentored by Arvinas biology staff in the basic day-to-day processes that support preclinical drug discovery for neurology indications.&nbsp; Through experiential learning, the selected candidate will become proficient in fundamental cellular and molecular biology techniques, the basic principles of pharmacology, data analysis, documentation, and interpretation.&nbsp; Under the guidance of staff, the intern will implement basic scientific techniques at the bench, critically read, process, and present selected papers from the relevant scientific literature, and a summary of their work at an end-of-summer student colloquium. This will be a full-time, wet-lab position, onsite position located at our headquarters in New Haven, CT (May-Aug 2026) Principal Responsibilities Key responsibilities of this role include, but are not limited to: Learn selected basic biology techniques from Arvinas staff with the goal of proficiency to the point of independently following detailed protocols to support in vitro pharmacology. Techniques Including: &nbsp;&nbsp; Cell culture, including CNS cell types. Evaluating cellular target engagement of putative ligands Quantitative protein analysis of PROTAC-mediated degradation and functional endpoints using in vitro CNS disease models (Western, luminescence-based readouts, and/or capillary immunoassay) Document experimental work in an Electronic Laboratory Notebook &amp; learn associated ELN protocols Attend project meetings and internal seminars at the direction of Mentor Read and present key papers from the relevant scientific literature at Summer Student Journal Club &nbsp; Qualifications Currently enrolled in an undergraduate degree program with a science discipline component Prior lab-based biology background, including coursework with a lab component, a plus but not required Prior independent research experience is a plus, but not required. Arvinas will not be providing VISA sponsorship for this position. You must have the ability to work without the need for a current or future VISA sponsorship. &nbsp; The duties of this role are generally conducted in a lab environment. Employees must be able, with or without an accommodation to lift/carry 15/30 pounds unassisted/assisted; work comfortable in a controlled environment with and around biological, infectious and hazardous materials; gown/degown PPE; use a computer; engage in communications via phone, video, and electronic messaging; engage in problem solving, analysis and dialogue; collaborate with others; maintain general availability during standard business hours. &nbsp; Education Enrolled in college or graduate level course work to support B.S. or B.A. in relevant scientific discipline. To learn more about Arvinas, please visit&nbsp;www.arvinas.com Arvinas is an equal opportunity employer. All qualified applicants will be considered for employment without regard to race, color, religion, sex, sexual orientation, gender identify, national origin, disability or protected veteran status.&nbsp; &nbsp;

Summer intern Neuroscience

Arvinas is a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. Arvinas uses its proprietary PROTAC Discovery Engine platform to engineer proteolysis targeting chimeras, or PROTAC targeted protein degraders, that are designed to harness the body’s own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. In addition to its robust preclinical pipeline of PROTAC protein degraders against validated and “undruggable” targets, the company has three investigational clinical-stage programs currently enrolling: &nbsp;ARV-102 for the treatment of patients with neurodegenerative disorders,ARV-393 for the treatment of patients with relapsed/refractory non-Hodgkin Lymphoma and potentially other lymphomas, and ARV-806, a KRAS G12D PROTAC for the treatment patients with solid tumors with KRAS G12D mutations. &nbsp; On August 8th 2025, the U.S. Food and Drug Administration (FDA) &nbsp;accepted the New Drug Application (NDA) for vepdegestrant- an investigational, orally bioavailable PROTAC estrogen receptor degrader- for its use as a monotherapy in the treatment of adults with estrogen receptor–positive (ER+), human epidermal growth factor receptor 2–negative (HER2-), ESR1-mutated advanced or metastatic breast cancer previously treated with endocrine-based therapy. In September 2025, Arvinas and Pfizer announced their plan to jointly select a third party for the out-licensing and commercialization of vepdegestrant. &nbsp; In April 2024, Arvinas entered into a transaction with Novartis, including a global license agreement for the development and commercialization of the clinical stage PROTAC&nbsp;androgen receptor protein degrader ARV-766 for the treatment of prostate cancer. The transaction closed in May 2024. #TeamArvinas is made up of passionate and curious employees, whose diverse thoughts and perspectives are highly valued. Arvinas employees embrace the freedom to pursue innovation, think creatively, and give back. They are driven by the company’s values and mission – to improve the lives of patients with serious diseases by pioneering therapies created with our revolutionary PROTAC protein degradation platform. We’re really excited about the work we’re doing inside and outside of Arvinas, and think you will be, too. But don’t just take our word for it – learn more about life at Arvinas and what employees have to say. &nbsp; For more information, please visit www.arvinas.com.&nbsp; Position Summary We are looking for a motivated individual to work as a summer intern (May 19 to August 15) within Neuroscience. This position will be focused on development of cellular and biochemical assays to support one of our preclinical programs. Under the guidance of staff, the intern will implement basic scientific techniques at the bench, critically read, process, and present selected papers from the relevant scientific literature, and a summary of their work at an end-of-summer student colloquium. This position reports to a Research Investigator or another member of the Neuroscience group. &nbsp; This will be a full-time, on-site position located at our headquarters in New Haven, CT. &nbsp; Principal Responsibilities Key responsibilities of this role include, but are not limited to: &gt;75% lab work: conduct experiments and analytical assays involving cell culture, protein detection, or protein:ligand interactions. Execution of assays to query targeted protein degradation: western blots, ELISA, reporter assays, etc. Use of lab automation for compound handling. Learn protein degrader pharmacology and data analysis. Apply excellent organizational skills to maintain lab stocks and lab cleanliness. Maintain clear experimental records and communicate well with supervisor and other team members. Deliver critical data by following provided protocols and guidance. Qualifications Motivated and productive individual with excellent communication skills who works effectively in a team setting. Prior lab experience is required. Experience with aseptic mammalian cell/tissue culture is required. Experience with antibody-based detection of proteins is strongly preferred. Some experience with 96- or 384-well plate-based assays is preferred (e.g., ELISA, colorometric assays, cell growth assays). Basic understanding of cell biology, molecular biology, and biochemistry through coursework. Organized, goal-oriented, and timeline-conscious. Other preferred skills and knowledge. Experimental documentation/lab notebook. Data presentation. Experience with Microsoft Office suite (Word, Excel, PowerPoint). A strong work ethic and willingness for continued learning. Arvinas will not be providing VISA sponsorship for this position. You must have the ability to work without the need for a current or future VISA sponsorship. &nbsp; The duties of this role are generally conducted in a lab environment. Employees must be able, with or without an accommodation to lift/carry 15/30 pounds unassisted/assisted; work comfortable in a controlled environment with and around biological, infectious and hazardous materials; gown/degown PPE; use a computer; engage in communications via phone, video, and electronic messaging; engage in problem solving, analysis and dialogue; collaborate with others; maintain general availability during standard business hours. &nbsp; Education Current 3rd or 4th year undergraduate or graduate student with a background in biological sciences and an interest in Neuroscience. &nbsp; &nbsp;To learn more about Arvinas, please visit www.arvinas.com Arvinas is an equal opportunity employer. All qualified applicants will be considered for employment without regard to race, color, religion, sex, sexual orientation, gender identify, national origin, disability or protected veteran status.&nbsp; &nbsp;

Summer Intern Neuroscience

Arvinas is a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. Arvinas uses its proprietary PROTAC Discovery Engine platform to engineer proteolysis targeting chimeras, or PROTAC targeted protein degraders, that are designed to harness the body’s own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. In addition to its robust preclinical pipeline of PROTAC protein degraders against validated and “undruggable” targets, the company has three investigational clinical-stage programs currently enrolling: &nbsp;ARV-102 for the treatment of patients with neurodegenerative disorders,ARV-393 for the treatment of patients with relapsed/refractory non-Hodgkin Lymphoma and potentially other lymphomas, and ARV-806, a KRAS G12D PROTAC for the treatment patients with solid tumors with KRAS G12D mutations. &nbsp; On August 8th 2025, the U.S. Food and Drug Administration (FDA) &nbsp;accepted the New Drug Application (NDA) for vepdegestrant- an investigational, orally bioavailable PROTAC estrogen receptor degrader- for its use as a monotherapy in the treatment of adults with estrogen receptor–positive (ER+), human epidermal growth factor receptor 2–negative (HER2-), ESR1-mutated advanced or metastatic breast cancer previously treated with endocrine-based therapy. In September 2025, Arvinas and Pfizer announced their plan to jointly select a third party for the out-licensing and commercialization of vepdegestrant. &nbsp; In April 2024, Arvinas entered into a transaction with Novartis, including a global license agreement for the development and commercialization of the clinical stage PROTAC&nbsp;androgen receptor protein degrader ARV-766 for the treatment of prostate cancer. The transaction closed in May 2024. #TeamArvinas is made up of passionate and curious employees, whose diverse thoughts and perspectives are highly valued. Arvinas employees embrace the freedom to pursue innovation, think creatively, and give back. They are driven by the company’s values and mission – to improve the lives of patients with serious diseases by pioneering therapies created with our revolutionary PROTAC protein degradation platform. We’re really excited about the work we’re doing inside and outside of Arvinas, and think you will be, too. But don’t just take our word for it – learn more about life at Arvinas and what employees have to say. &nbsp; For more information, please visit www.arvinas.com.&nbsp; Position Summary Arvinas is looking for an experienced Senior Medical Director with the passion and creativity to develop great medicines for neuromuscular and neurodegenerative diseases. The ideal candidate is a physician with experience of a global drug development program and global filing experience who is enthusiastic about applying their knowledge to the cause of patients around the globe who have no approved therapies for their disease. The individual will be a self-starter with excellent management and leadership capabilities who is seeking to lead and be part of an innovative team that will drive the drug development processes from start to finish. Reporting into the Vice President of Clinical Research, the Senior Medical Director will be primarily responsible for the strategy, development and execution of clinical research and development programs, including the leadership of the pivotal trials and filing activities. This position will serve as a key liaison between company and clinical investigators and establish credible relationships with opinion leaders, regulatory officials and other key stakeholders and partners. The successful candidate will be ready for a career defining experience and have the passion to drive a number of therapeutics for serious debilitating diseases to final approval. This role can be located at our headquarters in New Haven, CT or work with a hybrid or remote work arrangement from a location within the U.S. &nbsp; Principal Responsibilities Key responsibilities of this role include, but are not limited to: Partner with discovery and biology leadership and provide clinical input and guidance to develop the neuroscience corporate strategy. Responsible for trial design of Phase I/II/III research trials targeting neurologic diseases, requiring expertise and stewardship in the areas of CNS/Neurology Directly supervise and monitor trial conduct. Work closely with all functions of the organization and external partners to manage trial execution and investigators’ engagement. Collaborate in developing global regulatory plans and play a key role in regulatory meetings in partnership with regulatory affairs. Identify opportunities for external collaboration. Follow important developments and relevant trends in the scientific literature and develop/maintain contacts with external experts to support understanding of the candidate drug effects and to gain strategic insights to the further development of study and overall program. Develop effective relationships with external providers. Provide clinical assessments of potential in-licensing assets, identifying novel therapeutics opportunities as well as critical study design and execution challenges. Review written materials and provide editorial comments for clinical study reports and manuscripts. Ensure consistent practices with the highest ethical standards in compliance with internal SOPs, local regulations, and laws. Additional Responsibilities, including but not limited to: Design and develop clinical study protocols and associated clinical study documents and monitor required documentation in compliance with clinical development plans, GCP, and good medical practice. Participate in the selection of clinical investigators, providing guidance to investigators on a study. Provide medical supervision for contract research organizations and protocol procedures. Provide medical and scientific input in review of clinical data, patient medical safety data, and laboratory values; maintaining an ongoing assessment of the safety profile, and efficacy data as appropriate. Provide medical surveillance on Serious Adverse Event (SAE) reporting, and follow-ups. Direct and oversee the overall strategy for clinical drug product development and collaborating with Regulatory personnel in IND, CTA, and NDA submission activities as well as submission of IND safety reports. Lead the clinical aspect of interactions with regulatory agencies worldwide Participate in the planning, writing, and review of Clinical Study Reports, regulatory updates, and submissions. Assist with due diligence of new scientific developments. Analyze and interpret study data for abstracts or publication as required. Support corporate partnering efforts and business development activities by providing medical expertise and participating in partnership committees/task groups. Collaborate on overall company strategy and in licensing of new programs. Work with the financial group as needed to assist with the production of budgets and timelines for the clinical development team. Plan and lead clinical focus groups to create clinical trial and protocol designs. Ensure that operational activities are conducted in compliance with all pertinent regulatory or statutory requirements and in accordance with the scientific standards, ethical and professional values, management philosophy, and established priorities, policies, and practices of the Company. Lead the medical writing for the preparation of summarization of clinical trial data, including the preparation of study reports, integrated summaries, and clinical portions of package inserts and other product labeling. &nbsp; &nbsp; Qualifications A minimum of 5 years (7+ years strongly preferred) of biotech/pharma clinical development &nbsp;experience &nbsp;in &nbsp;neurological disease therapeutic areas. Experience across multiple stages of clinical development, from IND to NDA / BLA . Global clinical development experience required, and global filing experience strongly preferred. Technical (Medical and Scientific) experience evaluating targets/agents for in licensing or internal development. Experience supervising physicians and/or scientific staff in a management or team leader capacity highly desirable. Excellent interpersonal and public speaking skills are required for this high visibility position. Demonstrated ability to work in a matrix environment with cross-functional teams. Must be legally authorized to work in the US without the need for employer sponsorship now or at any time in the future. The duties of this role are generally conducted in a home office environment. Employees must be able, with or without an accommodation to use a computer; engage in communications via phone, video, and electronic messaging; engage in problem solving and non-linear thought, analysis, and dialogue; collaborate with others; maintain general availability during standard business hours. &nbsp; Education M.D. or equivalent degree is required. Formal training in the areas of Neurology is required. Arvinas is proud to offer a competitive package of base and incentive compensation as well as a comprehensive benefits program designed to support the health, wellness and financial security of our employees and their families. Benefits include group medical, vision and dental coverage, group and supplemental life insurance, and much more. To learn more about Arvinas, please visit&nbsp;www.arvinas.com Arvinas is an equal opportunity employer. All qualified applicants will be considered for employment without regard to race, color, religion, sex, sexual orientation, gender identify, national origin, disability or protected veteran status.&nbsp; &nbsp;

Senior Medical Director, Clinical Development - Neuroscience

Arvinas is a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. Arvinas uses its proprietary PROTAC Discovery Engine platform to engineer proteolysis targeting chimeras, or PROTAC targeted protein degraders, that are designed to harness the body’s own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. In addition to its robust preclinical pipeline of PROTAC protein degraders against validated and “undruggable” targets, the company has three investigational clinical-stage programs currently enrolling: &nbsp;ARV-102 for the treatment of patients with neurodegenerative disorders,ARV-393 for the treatment of patients with relapsed/refractory non-Hodgkin Lymphoma and potentially other lymphomas, and ARV-806, a KRAS G12D PROTAC for the treatment patients with solid tumors with KRAS G12D mutations. &nbsp; On August 8th 2025, the U.S. Food and Drug Administration (FDA) &nbsp;accepted the New Drug Application (NDA) for vepdegestrant- an investigational, orally bioavailable PROTAC estrogen receptor degrader- for its use as a monotherapy in the treatment of adults with estrogen receptor–positive (ER+), human epidermal growth factor receptor 2–negative (HER2-), ESR1-mutated advanced or metastatic breast cancer previously treated with endocrine-based therapy. In September 2025, Arvinas and Pfizer announced their plan to jointly select a third party for the out-licensing and commercialization of vepdegestrant. &nbsp; In April 2024, Arvinas entered into a transaction with Novartis, including a global license agreement for the development and commercialization of the clinical stage PROTAC&nbsp;androgen receptor protein degrader ARV-766 for the treatment of prostate cancer. The transaction closed in May 2024. #TeamArvinas is made up of passionate and curious employees, whose diverse thoughts and perspectives are highly valued. Arvinas employees embrace the freedom to pursue innovation, think creatively, and give back. They are driven by the company’s values and mission – to improve the lives of patients with serious diseases by pioneering therapies created with our revolutionary PROTAC protein degradation platform. We’re really excited about the work we’re doing inside and outside of Arvinas, and think you will be, too. But don’t just take our word for it – learn more about life at Arvinas and what employees have to say. &nbsp; For more information, please visit www.arvinas.com.&nbsp; Position Summary The Associate Director, Clinical Development &amp; Medical Affairs Operations plays an integral role in supporting the Medical Affairs organization. This position will be responsible for operational management of various projects and programs within Medical Affairs, and in partnership with cross-functional stakeholders. This position reports to the Executive Director, Medical Affairs Operations, and may be located at our headquarters in New Haven, CT or may be performed remotely from a location within the U.S. Principal Responsibilities Key responsibilities of this role include, but are not limited to: Provides operational support to Medical Affairs department and projects, including managing project timelines and budget Supports scientific publications operations, including publication tracking and reporting, author and agency coordination, document and journal submission management, compliance reviews, and maintenance of the Medical Affairs publications site Assists in the planning and execution of congress activities Assists in the planning and execution of Advisory Boards to include FMV assessments, tracking consultant agreements, and ensuring proper documentation Coordinates Medical Review Committee process for review of scientific exchange materials Manages the contracting process with external consultants/vendors and tracks progress Coordinates functional team meetings and generates and distributes meeting minutes Collaborates with internal cross functional stakeholders to ensure timely, quality execution of activities and projects Supports cross-functional communication across the CDMA functional teams through appropriate methods Supports high-priority, cross-functional initiatives that advance AI adoption, digital enablement, and other strategic CDMA priorities Supports the development and execution of the AI, automation, and digital enablement strategy for CDMA, driving solutions that enhance productivity, operational efficiency, and decision making across functions &nbsp; Qualifications Minimum of 5 years of experience in pharmaceutical/biotechnology industry or related fields Experience in medical affairs operations is preferred Must be able to work independently and collaboratively in a fast-paced, matrixed, team environment consisting of internal and external team members. Superior communication and interpersonal skills; effective interaction with cross functional team members. Demonstrated planning, organization, and time management skills including the ability to support and prioritize multiple projects. Demonstrated high level of competence with computers is essential; to include extensive experience with MS Office Applications is required Must be legally authorized to work in the US without the need for employer sponsorship now or at any time in the future. The duties of this role are generally conducted in a home office environment. Employees must be able, with or without an accommodation to use a computer; engage in communications via phone, video, and electronic messaging; engage in problem solving and non-linear thought, analysis, and dialogue; collaborate with others; maintain general availability during standard business hours. &nbsp; &nbsp; Education Bachelor’s degree in Life Sciences or Pharmacy. &nbsp; Arvinas is proud to offer a competitive package of base and incentive compensation as well as a comprehensive benefits program designed to support the health, wellness and financial security of our employees and their families. Benefits include group medical, vision and dental coverage, group and supplemental life insurance, and much more. To learn more about Arvinas, please visit&nbsp;www.arvinas.com Arvinas is an equal opportunity employer. All qualified applicants will be considered for employment without regard to race, color, religion, sex, sexual orientation, gender identify, national origin, disability or protected veteran status.&nbsp; &nbsp;

Associate Director, Clinical Development & Medical Affairs (CDMA) Operations & Innovation

Arvinas is a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. Arvinas uses its proprietary PROTAC Discovery Engine platform to engineer proteolysis targeting chimeras, or PROTAC targeted protein degraders, that are designed to harness the body’s own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. In addition to its robust preclinical pipeline of PROTAC protein degraders against validated and “undruggable” targets, the company has three investigational clinical-stage programs currently enrolling: &nbsp;ARV-102 for the treatment of patients with neurodegenerative disorders,ARV-393 for the treatment of patients with relapsed/refractory non-Hodgkin Lymphoma and potentially other lymphomas, and ARV-806, a KRAS G12D PROTAC for the treatment patients with solid tumors with KRAS G12D mutations. &nbsp; On August 8th 2025, the U.S. Food and Drug Administration (FDA) &nbsp;accepted the New Drug Application (NDA) for vepdegestrant- an investigational, orally bioavailable PROTAC estrogen receptor degrader- for its use as a monotherapy in the treatment of adults with estrogen receptor–positive (ER+), human epidermal growth factor receptor 2–negative (HER2-), ESR1-mutated advanced or metastatic breast cancer previously treated with endocrine-based therapy. In September 2025, Arvinas and Pfizer announced their plan to jointly select a third party for the out-licensing and commercialization of vepdegestrant. &nbsp; In April 2024, Arvinas entered into a transaction with Novartis, including a global license agreement for the development and commercialization of the clinical stage PROTAC&nbsp;androgen receptor protein degrader ARV-766 for the treatment of prostate cancer. The transaction closed in May 2024. #TeamArvinas is made up of passionate and curious employees, whose diverse thoughts and perspectives are highly valued. Arvinas employees embrace the freedom to pursue innovation, think creatively, and give back. They are driven by the company’s values and mission – to improve the lives of patients with serious diseases by pioneering therapies created with our revolutionary PROTAC protein degradation platform. We’re really excited about the work we’re doing inside and outside of Arvinas, and think you will be, too. But don’t just take our word for it – learn more about life at Arvinas and what employees have to say. &nbsp; For more information, please visit www.arvinas.com.&nbsp; Position Summary The position is a multi-disciplinary role that requires in-depth data management knowledge and external data management expertise, knowledge of clinical trial management activities and operations, understanding of central lab/analyzing lab processes and laboratory information management systems to ensure effective integrations and data flow with Clinical Database. The position coordinates and drives collaboration across cross-functional Study Team stakeholders (Data Management/Biostatistics/Programming, Clinical Operations, Translational Sciences, Bioanalytical Sciences, Clinical Pharmacology, CROs, external vendors, etc.) to ensure the collection of protocol-required biosample results and other external data to deliver timely, high-quality clinical study data fit for analysis and reporting. This position reports to the Head of Data Management and can be located at our headquarters in New Haven, CT or work remotely from a location within the U.S. &nbsp; Principal Responsibilities Key responsibilities of this role include, but are not limited to: Serves as the Arvinas subject matter expert (SME) and main point of contact (POC) for external data management activities across studies and data interchanges with the clinical database. Serves as the Arvinas SME and main POC for vendor oversight of the central labs and oversight of biosample sample movements between the central lab and analyzing lab. Oversees external data transfer agreements, specifications and data interchanges to the clinical database from 3rd party vendors/analyzing labs. Ensures data transfer specifications are aligned with protocol and analysis requirements. Develops and implements standardized data flows and integration of structured data in the clinical database using standardized, SDTM compliant DTSs for wide variety of data types. Provides ad hoc support for other technical data management activities such as: Arvinas EDC Acceptance Testing, review of EDC data structures for compliance with Standards and SDTM, review of external data file formats, verification of business analytics outputs, etc. Provides Arvinas DM oversight of activities performed by DM CRO/DM Vendors. Reviews and approves DM-related documentation, including contributing to Arvinas Data Interchange Plan and Arvinas Data Review and Data Quality Oversight Plan. Supports clinical study team data review using the JReview application, including user access administration and training; creates and maintains report objects in JReview; creates and maintains Data Listing Repository; provides technical support for data reviewers. Provides operational support for Clinical Study Teams and Biomarker Subteam. Supports process definition, Arvinas SOP and quality document development. Supports vendor contract and work order review. Provides oversight of central lab vendors and central lab vendor databases (LIMS), study documentation review (e.g., Lab Manual) and approval, lab kit review. Ensures alignment of central lab LIMS and the protocol and operational requirements for the study. POC for central lab Quality Events and Quality Incidents. Provides oversight of Analyzing Lab vendors (Data Transfer Specifications development, raw data transfers, biosample movements to/from laboratories). Performs PK biosample tracking for dose escalation clinical studies from Central Lab to PK Lab, in conjunction with Bioanalytical Scientist and Clinical Pharmacology; ensures the availability of biosample results for Cohort Review Committees and decision making. Provides oversight of biosample management and movement, especially between central lab and analyzing labs. Supports biosample movements from laboratories to Biorepository Vendor for long-term storage/biosample archive. Assesses sample loss risk and mitigates sample-related issues with CROs and lab vendors. Creates and approves biosample disposition-related documentation and ensures proper eTMF indexing of sample management/disposition related documentation. Encourages innovation, process improvement, and technology enhancements to increase Drug Development efficiency. Develops and maintains SOPs, Work Instructions, and other quality documents related to data management and biosample management. &nbsp; Qualifications 10+ years of clinical data science/data management, biometrics, and clinical operations experience supporting clinical drug development in an industry setting. &nbsp; In-depth data management knowledge and external data management expertise. In-depth understanding of central lab/analyzing lab processes and laboratory information management systems (LIMS), including biosample requisitioning and accessioning processes and other clinical operations activities. Extensive experience with clinical data interfaces and data exchanges with CROs and other vendors. Extensive experience working with Clinical CROs, analyzing laboratories, and other external vendors; experience creating work orders/budgets, establishing goals, risk mitigation, and ensuring performance standards are met by CRO and vendors. Expert understanding of relational databases. Proficient use of electronic data capture systems (e.g., Rave) and technical skills necessary to perform sponsor acceptance testing. Proficient use of study management tools/web-based vendor dashboards. Proficient use of J-Review; technological skills to create data review and cleaning listings, profiles, data visualizations in JReview. Strong understanding of the complex and interdependent relationships between data collection in EDC systems (e.g., Rave), externally loaded data in clinical databases, and protocol requirements. Strong understanding of data capture standards - CDASH, CDISC, and External Data SDTM standards for clinical study data collection. Understanding of clinical trial management activities and operations Understanding of GCP-ICH, SOPs, regulatory requirements, and Good Data Management Practices, including a strong understanding of 21 CFR Part 11 and GxP complaint systems. Proven experience handling and solving complex problems; implementing solutions &amp; best practices and guiding multiple projects and programs. Excellent written, verbal, and interpersonal communication skills. Strong project management and organizational skills; detail oriented. Strong negotiation skills and effective at influencing decision makers both internally and externally. Ability to work collaboratively and effectively in a cross-functional and culturally diverse team. Must be legally authorized to work in the US without the need for employer sponsorship now or at any time in the future. The duties of this role are generally conducted in a home office environment. Employees must be able, with or without an accommodation to use a computer; engage in communications via phone, video, and electronic messaging; engage in problem solving and non-linear thought, analysis, and dialogue; collaborate with others; maintain general availability during standard business hours. &nbsp; Education Bachelor’s degree in quantitative, scientific or health related field required. Arvinas is proud to offer a competitive package of base and incentive compensation as well as a comprehensive benefits program designed to support the health, wellness and financial security of our employees and their families. Benefits include group medical, vision and dental coverage, group and supplemental life insurance, and much more. To learn more about Arvinas, please visit&nbsp;www.arvinas.com Arvinas is an equal opportunity employer. All qualified applicants will be considered for employment without regard to race, color, religion, sex, sexual orientation, gender identify, national origin, disability or protected veteran status.&nbsp; &nbsp;

External Data Management & Biosample Operations Lead

Arvinas is a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. Arvinas uses its proprietary PROTAC Discovery Engine platform to engineer proteolysis targeting chimeras, or PROTAC targeted protein degraders, that are designed to harness the body’s own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. In addition to its robust preclinical pipeline of PROTAC protein degraders against validated and “undruggable” targets, the company has three investigational clinical-stage programs currently enrolling: &nbsp;ARV-102 for the treatment of patients with neurodegenerative disorders,ARV-393 for the treatment of patients with relapsed/refractory non-Hodgkin Lymphoma and potentially other lymphomas, and ARV-806, a KRAS G12D PROTAC for the treatment patients with solid tumors with KRAS G12D mutations. &nbsp; On August 8th 2025, the U.S. Food and Drug Administration (FDA) &nbsp;accepted the New Drug Application (NDA) for vepdegestrant- an investigational, orally bioavailable PROTAC estrogen receptor degrader- for its use as a monotherapy in the treatment of adults with estrogen receptor–positive (ER+), human epidermal growth factor receptor 2–negative (HER2-), ESR1-mutated advanced or metastatic breast cancer previously treated with endocrine-based therapy. In September 2025, Arvinas and Pfizer announced their plan to jointly select a third party for the out-licensing and commercialization of vepdegestrant. &nbsp; In April 2024, Arvinas entered into a transaction with Novartis, including a global license agreement for the development and commercialization of the clinical stage PROTAC&nbsp;androgen receptor protein degrader ARV-766 for the treatment of prostate cancer. The transaction closed in May 2024. #TeamArvinas is made up of passionate and curious employees, whose diverse thoughts and perspectives are highly valued. Arvinas employees embrace the freedom to pursue innovation, think creatively, and give back. They are driven by the company’s values and mission – to improve the lives of patients with serious diseases by pioneering therapies created with our revolutionary PROTAC protein degradation platform. We’re really excited about the work we’re doing inside and outside of Arvinas, and think you will be, too. But don’t just take our word for it – learn more about life at Arvinas and what employees have to say. &nbsp; For more information, please visit www.arvinas.com.&nbsp; &nbsp; Position Summary&nbsp; The Platform Biology summer internship position at Arvinas will focus on evaluating and developing 3D biology to include automation and high-content imaging to support Oncology and Neuroscience. This position will involve cell biology and biochemical techniques, use of automation equipment, and high-content imaging. The candidate will join a collaborative, multi-disciplinary team of biologists, biochemists, biophysicists, and chemists. This is a laboratory-based role that will work to automate the biology and staining of 3D spheroids (and possibly organoids) for deeper understanding of and screening for novel PROTACs.&nbsp; We are looking for a passionate and highly motivated individual who is enthusiastic about novel therapeutic applications, such as degraders, and wants to contribute to exploring new modalities of targeting proteins for degradation across neuroscience, oncology and immune-oncology space. This training opportunity allows the individual to learn the process of early drug discovery in a collaborative environment.&nbsp; This position reports to a Senior Research Scientist, Platform Biology and will be located at our headquarters in New Haven, CT. Principal Responsibilities Key responsibilities of this role include, but are not limited to: Cell culture including sterile technique for mammalian cell lines Live-cell assays to monitor, image and analyze 3D spheroids Cellular assays working to fix, permeabilize, and use immunofluorescence staining to research methods for 3D spheroid marker infiltration including tissue clearing while automating the staining process Develop, run and analyze data using high-content imaging instruments Cellular assays to monitor activity of degrader compounds (such as JESS, high-content, luminescence, fluorescence, NanoBRET) Data analysis and interpretation, as well as presenting data in team meetings. Meeting with key stakeholders outside of the project team to devise future experiments for downstream applications Major areas of focus will include utilizing established workflows to guide assay development and technical optimization, evaluating appropriate controls, and troubleshooting. Qualifications The candidate should be a highly motivated fast learner with flexibility and ability to multi-task, as well as a good lab citizen.&nbsp; Previous oncology or neuroscience experience is preferred Experience in cell culture is required. Experience with microscopy and high content imaging is a plus. Knowledge of ubiquitin-based proteasomal degradation is desired, but not a pre-requisite. Ability to work full-time (40 hours per week). Arvinas will not be providing VISA sponsorship for this position. You must have the ability to work without a need for a current or future VISA sponsorship. The duties of this role are generally conducted in a lab environment. Employees must be able, with or without an accommodation to lift/carry 15/30 pounds unassisted/assisted; work comfortable in a controlled environment with and around biological, infectious and hazardous materials; gown/degown PPE; use a computer; engage in communications via phone, video, and electronic messaging; engage in problem solving, analysis and dialogue; collaborate with others; maintain general availability during standard business hours. &nbsp; Education Preference to Master’s / PhD student currently enrolled in a program with a concentration in cell biology, immunology, pharmacology, biology, or related fields. Prior laboratory experience is a plus. To learn more about Arvinas, please visit www.arvinas.com Arvinas is an equal opportunity employer. All qualified applicants will be considered for employment without regard to race, color, religion, sex, sexual orientation, gender identify, national origin, disability or protected veteran status.&nbsp; &nbsp;

Summer Intern Platform Biology

Arvinas is a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. Arvinas uses its proprietary PROTAC Discovery Engine platform to engineer proteolysis targeting chimeras, or PROTAC targeted protein degraders, that are designed to harness the body’s own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. In addition to its robust preclinical pipeline of PROTAC protein degraders against validated and “undruggable” targets, the company has three investigational clinical-stage programs currently enrolling: &nbsp;ARV-102 for the treatment of patients with neurodegenerative disorders,ARV-393 for the treatment of patients with relapsed/refractory non-Hodgkin Lymphoma and potentially other lymphomas, and ARV-806, a KRAS G12D PROTAC for the treatment patients with solid tumors with KRAS G12D mutations. &nbsp; On August 8th 2025, the U.S. Food and Drug Administration (FDA) &nbsp;accepted the New Drug Application (NDA) for vepdegestrant- an investigational, orally bioavailable PROTAC estrogen receptor degrader- for its use as a monotherapy in the treatment of adults with estrogen receptor–positive (ER+), human epidermal growth factor receptor 2–negative (HER2-), ESR1-mutated advanced or metastatic breast cancer previously treated with endocrine-based therapy. In September 2025, Arvinas and Pfizer announced their plan to jointly select a third party for the out-licensing and commercialization of vepdegestrant. &nbsp; In April 2024, Arvinas entered into a transaction with Novartis, including a global license agreement for the development and commercialization of the clinical stage PROTAC&nbsp;androgen receptor protein degrader ARV-766 for the treatment of prostate cancer. The transaction closed in May 2024. #TeamArvinas is made up of passionate and curious employees, whose diverse thoughts and perspectives are highly valued. Arvinas employees embrace the freedom to pursue innovation, think creatively, and give back. They are driven by the company’s values and mission – to improve the lives of patients with serious diseases by pioneering therapies created with our revolutionary PROTAC protein degradation platform. We’re really excited about the work we’re doing inside and outside of Arvinas, and think you will be, too. But don’t just take our word for it – learn more about life at Arvinas and what employees have to say. &nbsp; For more information, please visit www.arvinas.com.&nbsp; Position Summary The Senior Director, IT R&amp;D and Clinical Systems serves as the strategic IT business partner for the R&amp;D and Clinical organizations, supporting early drug discovery through clinical development.&nbsp; This role is accountable for shaping and executing the R&amp;D and Clinical IT roadmap, translating scientific and clinical objectives into scalable, compliant, cost-effective, and integrated technology capabilities that enable high-quality science and operational excellence. This individual will work closely with Arvinas’ R&amp;D and Clinical team members to gain a deep understanding of the operations and objectives of each team and then develop multi-year IT capability roadmaps.&nbsp; The Senior Director has end-to-end accountability for all R&amp;D and Clinical systems, non-GxP laboratory IT systems, scientific computing environments, and high-performance computing (HPC) platforms that support computational chemistry, bioinformatics, structural biology, and modeling and simulation activities.&nbsp;&nbsp; This individual will ensure these environments are reliable, secure, performant, and well-integrated with upstream and downstream data platforms while remaining fit for rapid scientific iteration. The Senior Director will lead and develop a high-performing R&amp;D and Clinical IT team and will define, select, communicate, and manage&nbsp;&nbsp; strategic IT service providers and vendors to ensure the right mix of internal capabilities and external partnerships. This includes accountability for service quality, delivery outcomes, cost effectiveness, and alignment with scientific and clinical priorities. The position requires a strong understanding of integrated scientific and clinical workflows, regulated systems, and data flows across discovery, preclinical, and clinical environments.&nbsp; This position will work closely with core R&amp;D and Clinical functions at Arvinas, including biology, chemistry, cheminformatics, proteomics, compound management, laboratory automation, bioinformatics, DMPK, clinical data management and biostatistics, and clinical operations.&nbsp; The individual must have a proven ability to: Lead significant projects, Deliver, integrate, and maintain high-quality R&amp;D systems and Clinical systems, and Work with the teams to design a roadmap of the R&amp;D and Clinical systems for the next 3-5 years. This position reports to the Senior Vice President, Information Technology Systems &amp; Security and can be hybrid or located at our headquarters in New Haven, CT. Principal Responsibilities Key responsibilities of this role include, but are not limited to: Leadership Lead the divisional IT R&amp;D and Clinical Systems team, providing guidance, management, and direction for a future team of analysts and administrators (staffed as necessary from system count and complexity). Define, select, integrate, and manage strategic IT service providers and vendors. Provide technical leadership and guidance for the R&amp;D and Clinical teams at Arvinas.&nbsp; Provide clear direction for R&amp;D and Clinical managers on IT processes and systems. Develop and implement policies, controls, and processes in compliance with departmental and regulatory requirements. &nbsp; Projects and Systems Partner with business process owners and technology partners to elicit, analyze, translate, and document business processes. Prepare and communicate detailed capability roadmaps that define integration points and data strategy. Partner with Enterprise Data Architecture on developing and executing a data management strategy for R&amp;D and Clinical. Identify, scope, communicate, and prioritize business technology projects. Lead prioritized projects from concept to execution, often providing technical leadership. Manage, prioritize, and reduce to practice a portfolio of prioritized initiatives. Manage Request for Proposal Process (RFP) including documenting requirements, identifying and engaging vendors, leading product selection processes, overseeing contracting and negotiations, and managing product vendors. Provide technology leadership across R&amp;D and Clinical by proactively identifying emerging technologies and platforms (e.g., advanced analytics, AI/ML, automation) and assessing their potential applicability, value, and risk, while partnering with business stakeholders to evaluate, pilot, and integrate business-identified solutions in alignment with enterprise architecture, data strategy, and compliance requirements.&nbsp; Oversee the IT change control process (change control documentation, draft and execution of test plan, implementation of change in production) for Clinical systems. Coordinate global discussions and alignments on Clinical technology strategy, platforms, enhancements where applicable. Work with external parties’ personnel (e.g., CRO data teams) to analyze, define, and document data and information flows contributing to Clinical data management. Partner with external vendors and collaborators (e.g., CROs, academic partners, technology providers) to define, implement, and govern secure data flows and collaboration solutions, leveraging existing enterprise technologies (e.g., SFTP, SharePoint, and approved data exchange platforms) to ensure data integrity, accessibility, and compliance across R&amp;D and Clinical activities. &nbsp; Operations and Systems Develop, integrate, and maintain the IT operating budget for R&amp;D and Clinical systems. Manage the lifecycle of a large portfolio of systems across R&amp;D and Clinical. Ensure appropriate support solutions are in place and support knowledge is documented. Manage license renewals and negotiations. Regularly assess business usage and need. Act as an escalation point when required. Oversee the specification, integration, operation, maintenance, and evolution of both the high-performance computing (HPC) environment and lab computing environment (non-GxP), ensuring reliability, performance, security, cost-effectiveness, while aligning service levels and operating models with scientific needs and enterprise IT standards. Partner with IT Infrastructure and IT Security teams to ensure R&amp;D and Clinical systems, including scientific computing and laboratory environments, are secure, compliant, and aligned with enterprise architecture, security standards, and regulatory requirements, while balancing risk management with the operational needs of research and clinical activities. Ensure system lifecycle management practices are followed and anticipate and plan the upgrade and obsolescence pathways. In partnership with IT Governance, ensure risk management priorities are reflected in strategic plans and initiatives. Oversee internal and external reviews, audits, inspections, and investigations related to Clinical systems. Maintain and annually review policies, procedures, and standards related to GxP systems and lab computing operations. Work in concert with the user community to actively manage change and optimize solutions through their lifecycle. Support systems validation/testing to GxP compliance. &nbsp; Qualifications 12+ years of experience in life sciences IT support. Demonstrated experience serving as a senior IT business partner to R&amp;D and/or Clinical leadership, translating scientific and clinical strategies into multi-year technology and data capability roadmaps. Experience leading IT organizations, including operating model design, prioritization, integrated solutions, and portfolio management. Proven experience defining, selecting, and managing strategic IT service providers and vendors, including contract negotiation, service-level management, and cost optimization. Experience overseeing high-performance computing (HPC) and/or scientific computing environments. Familiarity with on-premise and/or cloud-based HPC architectures, capacity planning, and cost-performance tradeoffs. Experience with laboratory operational requirements and the balance between flexibility, reliability, and security in research environments. Demonstrated experience leading organizational change and driving adoption of new technologies within R&amp;D and Clinical organizations. Must have project management experience (Project Management Certification a plus). Strong interpersonal effectiveness, able to build trust and drive adoption of new software platforms. Demonstrated flexibility in being able to flex to operational work as needed. Excellent written and verbal communication skills. Very strong business analysis skills, problem-solving techniques, and follow-up Experience with GxP guidance and controls. Experience with Research processes (internal and external) and related systems (e.g. ELN, compound registration and inventory, assay and protocol management, SAR analysis and visualization solutions). Experience with Clinical processes and related systems (e.g. eTMF, SAS, CTMS). Broad understanding of enterprise IT infrastructure domains (networking, compute, operating systems, and cloud services) sufficient to guide architectural decisions and collaborate effectively with infrastructure and security teams. Experience with IT process, ITIL, and ticketing systems (e.g., ServiceNow, etc.) is highly desirable. Experience with Clinical electronic Trial Master File (eTMF) systems (especially Veeva Vault eTMF). Arvinas will not be providing VISA sponsorship for this position now or in the future. You must have the ability to work without a need for current or future VISA sponsorship. The duties of this role are generally conducted in a combination of company office and home office environments. Employees must be able, with or without an accommodation to lift/carry 15/30 pounds unassisted/assisted; work comfortable in a controlled environment with and around biological, infectious and hazardous materials; gown/degown PPE; use a computer; engage in communications via phone, video, and electronic messaging; engage in problem solving, analysis and dialogue; collaborate with others; maintain general availability during standard business hours. EDUCATION Bachelor’s degree in life sciences or IT disciplines (computer programming, software engineering, or related) with advanced degree (MS, PhD) preferred. The combination of education and experience enables exceptional skill level in conversational capability with R&amp;D and clinical colleagues, and understanding of research biology, chemistry, and clinical functions and their respective supporting IT systems and processes. &nbsp; Arvinas is proud to offer a competitive package of base and incentive compensation as well as a comprehensive benefits program designed to support the health, wellness and financial security of our employees and their families. Benefits include group medical, vision and dental coverage, group and supplemental life insurance, and much more. To learn more about Arvinas, please visit&nbsp;www.arvinas.com Arvinas is an equal opportunity employer. All qualified applicants will be considered for employment without regard to race, color, religion, sex, sexual orientation, gender identify, national origin, disability or protected veteran status.&nbsp; &nbsp;

Senior Director, IT R&D and Clinical Systems

Arvinas is a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. Arvinas uses its proprietary PROTAC Discovery Engine platform to engineer proteolysis targeting chimeras, or PROTAC targeted protein degraders, that are designed to harness the body’s own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. In addition to its robust preclinical pipeline of PROTAC protein degraders against validated and “undruggable” targets, the company has three investigational clinical-stage programs currently enrolling: &nbsp;ARV-102 for the treatment of patients with neurodegenerative disorders,ARV-393 for the treatment of patients with relapsed/refractory non-Hodgkin Lymphoma and potentially other lymphomas, and ARV-806, a KRAS G12D PROTAC for the treatment patients with solid tumors with KRAS G12D mutations. &nbsp; On August 8th 2025, the U.S. Food and Drug Administration (FDA) &nbsp;accepted the New Drug Application (NDA) for vepdegestrant- an investigational, orally bioavailable PROTAC estrogen receptor degrader- for its use as a monotherapy in the treatment of adults with estrogen receptor–positive (ER+), human epidermal growth factor receptor 2–negative (HER2-), ESR1-mutated advanced or metastatic breast cancer previously treated with endocrine-based therapy. In September 2025, Arvinas and Pfizer announced their plan to jointly select a third party for the out-licensing and commercialization of vepdegestrant. &nbsp; In April 2024, Arvinas entered into a transaction with Novartis, including a global license agreement for the development and commercialization of the clinical stage PROTAC&nbsp;androgen receptor protein degrader ARV-766 for the treatment of prostate cancer. The transaction closed in May 2024. #TeamArvinas is made up of passionate and curious employees, whose diverse thoughts and perspectives are highly valued. Arvinas employees embrace the freedom to pursue innovation, think creatively, and give back. They are driven by the company’s values and mission – to improve the lives of patients with serious diseases by pioneering therapies created with our revolutionary PROTAC protein degradation platform. We’re really excited about the work we’re doing inside and outside of Arvinas, and think you will be, too. But don’t just take our word for it – learn more about life at Arvinas and what employees have to say. &nbsp; For more information, please visit www.arvinas.com.&nbsp; Arvinas has an excellent opportunity for a summer internship in our Clinical Operations function to gain exposure, training, and experience supporting the following activities: Assist with study documentation and maintenance of trial master files (TMF) Support coordination with study sites, CROs, and cross-functional teams Help track study timelines and key deliverables This position reports to the Clinical Operations Lead and can be remote, hybrid, or located at our headquarters in New Haven, CT. Principal Responsibilities Key responsibilities of this role include, but are not limited to: Perform basic data review and quality control checks for GCP compliance Participate in team meetings and support operational reporting Assist with study documentation and maintenance of Trial Master File (TMF) Perform TMF filing, indexing, and quality control (QC) checks to ensure completeness and inspection readiness Track TMF metrics and follow up on missing or incomplete documents Support reconciliation activities (e.g., TMF vs. eTMF or vendor/CRO documents) Help ensure documents are filed in accordance with GCP and internal SOPs Support coordination with study sites, CROs, and cross-functional teams Help track study timelines and key deliverables Qualifications Strong interest in clinical research; prior experience not required Detail-oriented with good organizational skills Strong communication and teamwork abilities Proficiency in Microsoft Office Eager to learn in a fast-paced environment Arvinas will not be providing VISA sponsorship for this position now or in the future. You must have the ability to work without a need for current or future VISA sponsorship. The duties of this role are generally conducted in a combination of company office and home office environments. Employees must be able, with or without an accommodation to lift/carry 15/30 pounds unassisted/assisted; work comfortable in a controlled environment with and around biological, infectious and hazardous materials; gown/degown PPE; use a computer; engage in communications via phone, video, and electronic messaging; engage in problem solving, analysis and dialogue; collaborate with others; maintain general availability during standard business hours. EDUCATION Current rising juniors and seniors pursuing a bachelor’s degree, or master’s degree students in life sciences, public health, nursing, pharmacy, or a related field. Arvinas is proud to offer a competitive package of base and incentive compensation as well as a comprehensive benefits program designed to support the health, wellness and financial security of our employees and their families. Benefits include group medical, vision and dental coverage, group and supplemental life insurance, and much more. To learn more about Arvinas, please visit&nbsp;www.arvinas.com Arvinas is an equal opportunity employer. All qualified applicants will be considered for employment without regard to race, color, religion, sex, sexual orientation, gender identify, national origin, disability or protected veteran status.&nbsp; &nbsp;

Summer Intern - Clinical Operations

Arvinas is a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. Arvinas uses its proprietary PROTAC Discovery Engine platform to engineer proteolysis targeting chimeras, or PROTAC targeted protein degraders, that are designed to harness the body’s own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. In addition to its robust preclinical pipeline of PROTAC protein degraders against validated and “undruggable” targets, the company has three investigational clinical-stage programs currently enrolling: &nbsp;ARV-102 for the treatment of patients with neurodegenerative disorders,ARV-393 for the treatment of patients with relapsed/refractory non-Hodgkin Lymphoma and potentially other lymphomas, and ARV-806, a KRAS G12D PROTAC for the treatment patients with solid tumors with KRAS G12D mutations. &nbsp; On August 8th 2025, the U.S. Food and Drug Administration (FDA) &nbsp;accepted the New Drug Application (NDA) for vepdegestrant- an investigational, orally bioavailable PROTAC estrogen receptor degrader- for its use as a monotherapy in the treatment of adults with estrogen receptor–positive (ER+), human epidermal growth factor receptor 2–negative (HER2-), ESR1-mutated advanced or metastatic breast cancer previously treated with endocrine-based therapy. In September 2025, Arvinas and Pfizer announced their plan to jointly select a third party for the out-licensing and commercialization of vepdegestrant. In April 2024, Arvinas entered into a transaction with Novartis, including a global license agreement for the development and commercialization of the clinical stage PROTAC&nbsp;androgen receptor protein degrader ARV-766 for the treatment of prostate cancer. The transaction closed in May 2024. #TeamArvinas is made up of passionate and curious employees, whose diverse thoughts and perspectives are highly valued. Arvinas employees embrace the freedom to pursue innovation, think creatively, and give back. They are driven by the company’s values and mission – to improve the lives of patients with serious diseases by pioneering therapies created with our revolutionary PROTAC protein degradation platform. We’re really excited about the work we’re doing inside and outside of Arvinas, and think you will be, too. But don’t just take our word for it – learn more about life at Arvinas and what employees have to say. For more information, please visit&nbsp;www.arvinas.com.&nbsp; Position Summary The Senior Director, Clinical Operations provides strategic and operational leadership for assigned oncology clinical programs, with a strong focus on first-in-human (FIH) and dose-escalation studies. This role is accountable for end-to-end execution, ensuring studies are delivered with high quality, regulatory compliance, and speed. The position requires demonstrated leadership in CRO and vendor management, cross-functional decision-making, and risk mitigation in complex global trials. This role may oversee one or more studies or programs and serves as a key operational partner to Clinical Development, Regulatory, Biometrics, Quality, and Sourcing. This position reports to senior Clinical Operations leadership and may be remote, hybrid, or based in New Haven, CT. Principal Responsibilities Leadership Expectations This role is expected to operate as a leader, anticipating issues, driving alignment, and holding teams and vendors accountable for delivery. Strategic and Leadership Responsibilities Provide operational leadership and accountability for oncology clinical trials, including FIH and dose-escalation studies. Translate asset and governance decisions into executable operational plans, timelines, and resourcing strategies. Lead and influence cross-functional teams to drive timely decision-making. Lead operational planning and execution of Clinical Pharmacology studies (e.g., FIH, SAD/MAD, food effect, DDI, QTc, bioavailability studies). Develop and maintain the study operational plan, timelines, and cross-functional deliverables in collaboration with Clinical Pharmacology, Data Management, Biostats, Safety, and Regulatory. Coordinate study start-up, site readiness, and operational oversight, including monitoring enrollment, dosing milestones, and data delivery timelines. Lead cross-functional study team meetings, track risks and issues, and ensure timely resolution to maintain study timelines. Ensure Trial Master File (TMF) completeness and inspection readiness throughout the study lifecycle. Provide regular study status updates to program leadership, highlighting progress, risks, and mitigation strategies. Study Execution and Oversight Lead the end-to-end operational execution of assigned studies from startup through close-out. Own study timelines, deliverables, and operational KPIs; proactively identify and mitigate risks. Oversee FIH dose-escalation execution, including cohort management and safety review coordination. Drive feasibility, country and site strategy, and global startup execution. Ensure investigator meetings, SIVs, and training strategies are aligned with study complexity. CRO and Vendor Management Provide strong oversight and governance of CROs and vendors. Partner with Sourcing and Finance on CRO selection, contracting, change orders, and budget oversight. Ensure CRO execution aligns with sponsor expectations for speed, accountability, and quality. Lead regular vendor governance and performance reviews. Compliance and Quality Ensure studies are conducted in accordance with ICH/GCP, FDA, EMA, and global regulations. Partner with QA to ensure readiness inspection. Oversee monitoring strategies, data review cadence, and clinical data quality oversight. Cross-Functional Collaboration Act as a key operational partner to Clinical Development, Regulatory Affairs, Biometrics, Data Management, and QA. Provide clear communication on progress, risks, and decisions. Qualifications Experience 15+ years of clinical operations experience in drug development. Demonstrated leadership in oncology clinical trials, including FIH and dose-escalation studies. Proven experience leading global studies and managing CROs and vendors. Experience in fast-paced early development environments. Skills and Competencies Strong leadership, judgment, and decision-making skills. Ability to balance speed and accountability. Excellent stakeholder management and communication skills. Deep understanding of clinical trial operations and regulatory requirements. Education Bachelor’s degree in a clinical or science-based field required; advanced degree preferred. &nbsp; &nbsp; &nbsp; &nbsp; Arvinas is proud to offer a competitive package of base and incentive compensation as well as a comprehensive benefits program designed to support the health, wellness and financial security of our employees and their families. Benefits include group medical, vision and dental coverage, group and supplemental life insurance, and much more. To learn more about Arvinas, please visit www.arvinas.com Arvinas is an equal opportunity employer. All qualified applicants will be considered for employment without regard to race, color, religion, sex, sexual orientation, gender identify, national origin, disability or protected veteran status.&nbsp; &nbsp;

Senior Director of Clinical Operations

Arvinas is a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. Arvinas uses its proprietary PROTAC Discovery Engine platform to engineer proteolysis targeting chimeras, or PROTAC targeted protein degraders, that are designed to harness the body’s own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. In addition to its robust preclinical pipeline of PROTAC protein degraders against validated and “undruggable” targets, the company has three investigational clinical-stage programs currently enrolling: &nbsp;ARV-102 for the treatment of patients with neurodegenerative disorders,ARV-393 for the treatment of patients with relapsed/refractory non-Hodgkin Lymphoma and potentially other lymphomas, and ARV-806, a KRAS G12D PROTAC for the treatment patients with solid tumors with KRAS G12D mutations. &nbsp; On August 8th 2025, the U.S. Food and Drug Administration (FDA) &nbsp;accepted the New Drug Application (NDA) for vepdegestrant- an investigational, orally bioavailable PROTAC estrogen receptor degrader- for its use as a monotherapy in the treatment of adults with estrogen receptor–positive (ER+), human epidermal growth factor receptor 2–negative (HER2-), ESR1-mutated advanced or metastatic breast cancer previously treated with endocrine-based therapy. In September 2025, Arvinas and Pfizer announced their plan to jointly select a third party for the out-licensing and commercialization of vepdegestrant. &nbsp; In April 2024, Arvinas entered into a transaction with Novartis, including a global license agreement for the development and commercialization of the clinical stage PROTAC&nbsp;androgen receptor protein degrader ARV-766 for the treatment of prostate cancer. The transaction closed in May 2024. #TeamArvinas is made up of passionate and curious employees, whose diverse thoughts and perspectives are highly valued. Arvinas employees embrace the freedom to pursue innovation, think creatively, and give back. They are driven by the company’s values and mission – to improve the lives of patients with serious diseases by pioneering therapies created with our revolutionary PROTAC protein degradation platform. We’re really excited about the work we’re doing inside and outside of Arvinas, and think you will be, too. But don’t just take our word for it – learn more about life at Arvinas and what employees have to say. &nbsp; For more information, please visit www.arvinas.com.&nbsp; Position Summary The internship project will explore approaches to ternary complex modeling and have a focus on evaluating internal, commercial, and literature workflows and tools. Collaborating closely with members of the Arvinas CADD team, the intern will configure, run, and benchmark ternary complex modeling workflows. The intern will present results at CADD team meetings and will summarize their work as a talk or poster at Arvinas at the conclusion of the internship. This position reports to the Senior Research Investigator, Computational Chemistry and can be located remotely within the U.S. Principal Responsibilities Key responsibilities of this role include, but are not limited to: Explore state of the art tools for protein structure prediction and ternary complex modeling. Collect and prepare a comprehensive dataset of published ternary complex X-ray and cryo-EM structures. Rigorously evaluate the performance of different ternary complex modeling approaches. Prepare and present results at an internal Arvinas function at the conclusion of the internship. Qualifications Experience using protein structure predictions methods (AlphaFold, RoseTTAFold, Boltz, etc.) is required. Experience with a cheminformatics toolkit (RDKit, OpenEye, Schrodinger, etc.) is required. Proficiency in Python programming required. Experience using version control (GitHub, GitLab, Bitbucket, etc.) required. Knowledge of and experience with at least one ML framework (TensorFlow, PyTorch or Keras) is desirable. Experience working on medicinal chemistry projects is desirable. Must be able to work effectively in both independent and team contexts. Arvinas will not be providing VISA sponsorship for this position now or in the future. You must have the ability to work without a need for current or future VISA sponsorship. The duties of this role are generally conducted in a combination of company office and home office environments. Employees must be able, with or without an accommodation to lift/carry 15/30 pounds unassisted/assisted; work comfortable in a controlled environment with and around biological, infectious and hazardous materials; gown/degown PPE; use a computer; engage in communications via phone, video, and electronic messaging; engage in problem solving, analysis and dialogue; collaborate with others; maintain general availability during standard business hours. &nbsp; EDUCATION Computational Chemistry/Biology, Chemistry, Biology, or Computer Science major. Completion of classes in Computational Chemistry, Chemistry, and/or Molecular Biology &amp; Biophysics strongly preferred. Preference for doctoral graduate students nearing degree completion. #LI-Remote &nbsp; Arvinas is proud to offer a competitive package of base and incentive compensation as well as a comprehensive benefits program designed to support the health, wellness and financial security of our employees and their families. Benefits include group medical, vision and dental coverage, group and supplemental life insurance, and much more. To learn more about Arvinas, please visit www.arvinas.com Arvinas is an equal opportunity employer. All qualified applicants will be considered for employment without regard to race, color, religion, sex, sexual orientation, gender identify, national origin, disability or protected veteran status.&nbsp; &nbsp;

Summer Intern - Computational Chemistry & Artificial Intelligence

Arvinas is a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. Arvinas uses its proprietary PROTAC Discovery Engine platform to engineer proteolysis targeting chimeras, or PROTAC targeted protein degraders, that are designed to harness the body’s own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. In addition to its robust preclinical pipeline of PROTAC protein degraders against validated and “undruggable” targets, the company has three investigational clinical-stage programs currently enrolling: &nbsp;ARV-102 for the treatment of patients with neurodegenerative disorders,ARV-393 for the treatment of patients with relapsed/refractory non-Hodgkin Lymphoma and potentially other lymphomas, and ARV-806, a KRAS G12D PROTAC for the treatment patients with solid tumors with KRAS G12D mutations. &nbsp; On August 8th 2025, the U.S. Food and Drug Administration (FDA) &nbsp;accepted the New Drug Application (NDA) for vepdegestrant- an investigational, orally bioavailable PROTAC estrogen receptor degrader- for its use as a monotherapy in the treatment of adults with estrogen receptor–positive (ER+), human epidermal growth factor receptor 2–negative (HER2-), ESR1-mutated advanced or metastatic breast cancer previously treated with endocrine-based therapy. In September 2025, Arvinas and Pfizer announced their plan to jointly select a third party for the out-licensing and commercialization of vepdegestrant. &nbsp; In April 2024, Arvinas entered into a transaction with Novartis, including a global license agreement for the development and commercialization of the clinical stage PROTAC&nbsp;androgen receptor protein degrader ARV-766 for the treatment of prostate cancer. The transaction closed in May 2024. #TeamArvinas is made up of passionate and curious employees, whose diverse thoughts and perspectives are highly valued. Arvinas employees embrace the freedom to pursue innovation, think creatively, and give back. They are driven by the company’s values and mission – to improve the lives of patients with serious diseases by pioneering therapies created with our revolutionary PROTAC protein degradation platform. We’re really excited about the work we’re doing inside and outside of Arvinas, and think you will be, too. But don’t just take our word for it – learn more about life at Arvinas and what employees have to say. &nbsp; For more information, please visit www.arvinas.com.&nbsp; Position Summary &nbsp; We are seeking a highly motivated Manager, Clinical Biomarker Assays, Translational Science, Neuroscience with biomarker expertise to lead and execute clinical biomarker assay &nbsp;development, validation and implementation activities to support our neuroscience clinical programs. This individual will perform as the Clinical Biomarker Assay Lead within Translational Science to support Neuroscience programs, and will be responsible for clinical biomarker CROs evaluation and oversight, clinical biomarker assay development and validation, clinical sample testing execution, and high-quality biomarker data generation and transfer to support assessment of pharmacodynamics including target engagement, patient stratification, and disease progression. The successful candidate will combine strong scientific rigor with cross-functional leadership and a track record of overseeing development of biomarker assays for utilization in clinical studies. This position reports to Director, Translational Science – Neuroscience and can be located at our headquarters in New Haven, CT or work remotely from a location within the U.S. &nbsp; Principal Responsibilities Key responsibilities of this role include, but are not limited to: Conduct scientific and operational due diligence and selection of external biomarker CROs and assay platforms, leading vendor due diligence processes including, but not limited to assessment of biomarker technology, evaluations of biomarker assay feasibility, analytical performance and validation characteristics, and overall technical capability. Lead and oversee development, qualification, and validation of clinical biomarker assays (e.g., ELISA, Simoa, MSD, LC-MS/MS, Olink/SomaScan, NGS etc) in collaboration with internal teams and CROs, including review of assay analytical validation plans, biomarker reports, and technical documentation to ensure timely clinical biomarker assay deliverables and biomarker assay performance meets regulatory and industry standards for clinical use (e.g., GCLP, CLIA, CAP as applicable). Oversee external CROs/labs performing clinical biomarker testing, including vendor management. assay transfer and clinical sample testing. Ensure high-quality biomarker data generation, QC, and timely data transfer Cross-functional collaboration with Translational Science Lead, Clinical Operations, Biosample Operations, Data Management, and external vendors to ensure execution of biomarker readouts in our clinical studies. &nbsp; &nbsp; Qualifications Required Qualifications 5+ years (industry preferred) in clinical biomarker assay development and/or bioanalytical sciences. Demonstrated experience managing external CROs and central laboratories Demonstrated experience with protein biomarkers (such as fluid (including CSF) and tissue biomarkers, blood-based biomarkers), and genomic platforms (e.g., Simoa, MSD, Olink, mass spectrometry, NGS) &nbsp;Experience with neuroimaging biomarkers (e.g., PET, MRI) and/or digital biomarkers preferred. Familiarity with clinical data standards and biomarker data transfer processes. Experience working in neuroscience and/or rare diseases such as Parkinson’s disease, PSP, Alzheimer’s disease, or related disorders preferred Experience supporting IND-enabling or early-phase clinical trials preferred Demonstrated success in working cross-functionally within multidisciplinary teams. Excellent communication, organizational, and problem-solving skills, with the ability to operate independently in a matrixed environment. Arvinas will not be providing VISA sponsorship for this position. You must have the ability to work without a need for current or future VISA sponsorship. The duties of this role are generally conducted in a combination of company office and home office environments. Employees must be able, with or without an accommodation use a computer; engage in communications via phone, video, and electronic messaging; engage in problem solving, analysis and dialogue; collaborate with others; maintain general availability during standard business hours. Education D. in Neuroscience, Neurobiology, Molecular Biology, Pharmacology, or a related life science field. &nbsp; #LI-Remote Arvinas is proud to offer a competitive package of base and incentive compensation as well as a comprehensive benefits program designed to support the health, wellness and financial security of our employees and their families. Benefits include group medical, vision and dental coverage, group and supplemental life insurance, and much more. To learn more about Arvinas, please visit www.arvinas.com &nbsp; Arvinas is an equal opportunity employer. All qualified applicants will be considered for employment without regard to race, color, religion, sex, sexual orientation, gender identify, national origin, disability or protected veteran status.&nbsp; &nbsp;

Manager, Clinical Biomarker Assays, Translational Science - Neuroscience

Arvinas is a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. Arvinas uses its proprietary PROTAC Discovery Engine platform to engineer proteolysis targeting chimeras, or PROTAC targeted protein degraders, that are designed to harness the body’s own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. In addition to its robust preclinical pipeline of PROTAC protein degraders against validated and “undruggable” targets, the company has three investigational clinical-stage programs currently enrolling: &nbsp;ARV-102 for the treatment of patients with neurodegenerative disorders,ARV-393 for the treatment of patients with relapsed/refractory non-Hodgkin Lymphoma and potentially other lymphomas, and ARV-806, a KRAS G12D PROTAC for the treatment patients with solid tumors with KRAS G12D mutations. &nbsp; On August 8th 2025, the U.S. Food and Drug Administration (FDA) &nbsp;accepted the New Drug Application (NDA) for vepdegestrant- an investigational, orally bioavailable PROTAC estrogen receptor degrader- for its use as a monotherapy in the treatment of adults with estrogen receptor–positive (ER+), human epidermal growth factor receptor 2–negative (HER2-), ESR1-mutated advanced or metastatic breast cancer previously treated with endocrine-based therapy. In September 2025, Arvinas and Pfizer announced their plan to jointly select a third party for the out-licensing and commercialization of vepdegestrant. &nbsp; In April 2024, Arvinas entered into a transaction with Novartis, including a global license agreement for the development and commercialization of the clinical stage PROTAC&nbsp;androgen receptor protein degrader ARV-766 for the treatment of prostate cancer. The transaction closed in May 2024. #TeamArvinas is made up of passionate and curious employees, whose diverse thoughts and perspectives are highly valued. Arvinas employees embrace the freedom to pursue innovation, think creatively, and give back. They are driven by the company’s values and mission – to improve the lives of patients with serious diseases by pioneering therapies created with our revolutionary PROTAC protein degradation platform. We’re really excited about the work we’re doing inside and outside of Arvinas, and think you will be, too. But don’t just take our word for it – learn more about life at Arvinas and what employees have to say. &nbsp; For more information, please visit www.arvinas.com.&nbsp; Position SummaryWe are seeking an experienced Director of Clinical Operations with deep expertise in neuroscience drug development to lead the global execution of early- and mid-stage clinical trials. This role will focus on Phase I/II (including Phase 1b) studies in neurodegenerative diseases, including Parkinson’s Disease (PD), atypical parkinsonism (e.g., PSP), SBMA, and related indications. This is a critical leadership role for a hands-on clinical operations expert with a proven track record in designing, operationalizing, and executing complex neuroscience trials. The ideal candidate brings deep experience overseeing CROs and external vendors, ensuring delivery of studies with operational excellence, high quality, and inspection readiness. The Director will be responsible for translating clinical development strategy into seamless, high-quality execution, from IND-enabling activities through early clinical development, ensuring studies are delivered on time, within budget, and in compliance with GCP, ICH guidelines, and company SOPs. This individual will also play a key role in building and scaling clinical operations infrastructure, processes, and teams to support a growing neuroscience pipeline. This position reports to the Executive Director, Clinical Operations and may be based remotely within the U.S. Principal ResponsibilitiesKey responsibilities include, but are not limited to: Lead end-to-end clinical operations for global early-phase neuroscience trials, ensuring delivery against timelines, budget, quality, and enrollment targets. Serve as the primary operational lead for CRO oversight, driving accountability, performance, and partnership to ensure execution excellence and high-quality data delivery. Provide strategic and technical leadership in the planning and execution of complex neuroscience studies, including dose-escalation, cohort expansion, and rare disease trial designs. Translate clinical development strategy into operational plans, ensuring alignment across cross-functional stakeholders and external partners. Build, lead, and develop a high-performing clinical operations team, including hiring, training, and resource prioritization aligned with program needs. Establish and optimize clinical operations infrastructure, including SOPs, systems, processes, and KPIs to support scalable and compliant trial execution. Oversee vendor selection, contracting, and management, including CROs and specialty vendors; ensure performance metrics are defined and met. Proactively identify and mitigate operational risks, particularly for early-phase and rare disease studies. Partner cross-functionally with Clinical Development, Medical, Regulatory, Biometrics, CMC, Supply Chain, Legal, IT, and Finance to ensure integrated execution. Collaborate with key opinion leaders (KOLs) and investigators to inform protocol design and feasibility. Ensure studies are conducted in compliance with GCP, ICH guidelines, and regulatory requirements, maintaining inspection readiness at all times. Oversee clinical documentation and deliverables, including protocols, IBs, DSURs, and study reports, in collaboration with medical writing and clinical teams. Monitor and report on clinical trial performance metrics (KPIs), including enrollment, quality, timelines, and budget. Foster a collaborative, accountable, and execution-focused culture within the clinical operations function and across stakeholders. Qualifications 12+ years of clinical operations experience, with significant hands-on leadership of early-phase clinical trials, including Phase I/II studies. Deep expertise in neuroscience clinical trials, particularly in neurodegenerative diseases (e.g., PD, PSP, SBMA, ALS). Demonstrated success in CRO oversight and vendor management, with a strong ability to drive performance, accountability, and quality. Proven experience advancing programs from preclinical/IND-enabling through early clinical development. 5+ years of people management experience, with the ability to build and lead high-performing teams. Strong understanding of GCP, ICH guidelines, and global regulatory requirements. Experience in biotech or fast-paced clinical-stage environments, with the ability to operate with agility and accountability. Excellent strategic thinking, problem-solving, and risk management skills. Strong communication and stakeholder management skills, with the ability to influence at senior levels. Demonstrated ability to manage budgets, timelines, and competing priorities across multiple programs. Experience with INDs and early clinical development is highly preferred. Clinical pharmacology and/or dose-escalation study experience is desirable. Willingness to travel as needed. Arvinas will not be providing VISA sponsorship for this position. You must have the ability to work without a need for current or future VISA sponsorship. The duties of this role are generally conducted in a combination of company office and home office environments. Employees must be able, with or without an accommodation use a computer; engage in communications via phone, video, and electronic messaging; engage in problem solving, analysis and dialogue; collaborate with others; maintain general availability during standard business hours. &nbsp; Preferred Experience Experience in Parkinson’s Disease, PSP, SBMA, ALS, or related neurodegenerative disorders. Experience with rare disease trials, including patient recruitment challenges and innovative trial designs. Familiarity with decentralized trial elements and digital health technologies. Experience with patient registries and natural history studies. Prior experience building or scaling clinical operations infrastructure in a growing biotech. Education Bachelor’s degree in Life Sciences, Pharmacy, or related field required; advanced degree preferred. &nbsp; Arvinas is proud to offer a competitive package of base and incentive compensation as well as a comprehensive benefits program designed to support the health, wellness and financial security of our employees and their families. Benefits include group medical, vision and dental coverage, group and supplemental life insurance, and much more. To learn more about Arvinas, please visit www.arvinas.com Arvinas is an equal opportunity employer. All qualified applicants will be considered for employment without regard to race, color, religion, sex, sexual orientation, gender identify, national origin, disability or protected veteran status.&nbsp; &nbsp;

Director of Clinical Operations (Neuroscience)

Arvinas is a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. Arvinas uses its proprietary PROTAC Discovery Engine platform to engineer proteolysis targeting chimeras, or PROTAC targeted protein degraders, that are designed to harness the body’s own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. In addition to its robust preclinical pipeline of PROTAC protein degraders against validated and “undruggable” targets, the company has three investigational clinical-stage programs currently enrolling: &nbsp;ARV-102 for the treatment of patients with neurodegenerative disorders,ARV-393 for the treatment of patients with relapsed/refractory non-Hodgkin Lymphoma and potentially other lymphomas, and ARV-806, a KRAS G12D PROTAC for the treatment patients with solid tumors with KRAS G12D mutations. &nbsp; On August 8th 2025, the U.S. Food and Drug Administration (FDA) &nbsp;accepted the New Drug Application (NDA) for vepdegestrant- an investigational, orally bioavailable PROTAC estrogen receptor degrader- for its use as a monotherapy in the treatment of adults with estrogen receptor–positive (ER+), human epidermal growth factor receptor 2–negative (HER2-), ESR1-mutated advanced or metastatic breast cancer previously treated with endocrine-based therapy. In September 2025, Arvinas and Pfizer announced their plan to jointly select a third party for the out-licensing and commercialization of vepdegestrant. &nbsp; In April 2024, Arvinas entered into a transaction with Novartis, including a global license agreement for the development and commercialization of the clinical stage PROTAC&nbsp;androgen receptor protein degrader ARV-766 for the treatment of prostate cancer. The transaction closed in May 2024. #TeamArvinas is made up of passionate and curious employees, whose diverse thoughts and perspectives are highly valued. Arvinas employees embrace the freedom to pursue innovation, think creatively, and give back. They are driven by the company’s values and mission – to improve the lives of patients with serious diseases by pioneering therapies created with our revolutionary PROTAC protein degradation platform. We’re really excited about the work we’re doing inside and outside of Arvinas, and think you will be, too. But don’t just take our word for it – learn more about life at Arvinas and what employees have to say. &nbsp; For more information, please visit www.arvinas.com.&nbsp; Position Summary Arvinas is seeking a highly motivated and experienced Asset Team Leader to lead cross-functional teams that are accountable, in partnership with the functional leaders on the Asset Team, for the strategy and seamless execution of early oncology development programs. The successful candidate will work to recommend and drive the strategy of early oncology assets and execution against planned timelines. The Asset Team Leader will lead a cross-functional team including clinical research, clinical operations, regulatory affairs, clinical pharmacology, translational/companion diagnostics, CMC, non-clinical, medical affairs and New Product Planning to deliver against the program strategy. The successful candidate will have experience in early phase development of oncology or related programs. This role will report to the SVP, Asset Strategy and Team Leadership and can be remote, hybrid, or located at our headquarters in New Haven, CT. &nbsp; Principal Responsibilities Key responsibilities of this role include, but are not limited to: Lead cross-functional oncology asset teams and act as main point of contact and program representative to executive management Negotiate with and influence key internal and external stakeholders Drive generation and execution of the program strategy and Integrated Development Plans with a multidisciplinary matrixed team.&nbsp; Lead alignment on plans with governance and executive management. Create program strategies that maximize the overall long-term Work closely to coordinate strategic and operational efforts with key functions, including Clinical Research, Clinical Operations, Regulatory, CMC, New Product Planning and Project Management to ensure strategic alignment and seamless execution to deliver the greatest value to patients, physicians, payors, and Arvinas Partnering with Research to move programs out of exploratory research and into development Collaborate with functional leads to create and evaluate detailed scenario plans based on the external landscape and business needs Create, manage and optimize timelines, financial accountability, and other vital metrics for multiple projects simultaneously and ensure effective coordination of activities and deliverables across all functions Work closely with the Project Manager on program progress, cost, resource allocation, timelines, etc. and collaborate with functional team leads to proactively identify risks, resolve issues and optimize performance Drive team objective setting, prioritization and performance to ensure adherence to plan and strategy Drive proactive risk management, issue identification and resolution, and contingency planning Create a positive team environment in order to achieve the highest level of performance by instilling trust and ensuring clear, transparent communications, and building consensus behind the overall goal/vision for the programs Represent the programs at governance and decision-making meetings Lead and/or support other corporate objectives involving the assets including Board meeting preparation, earnings preparations and corporate presentations Lead the External Engagement subteam Supervise and mentor junior staff &nbsp; Qualifications Significant drug development leadership experience, with history of effective management of cross functional teams, key external stakeholders and partners, specifically including leadership of early oncology asset teams Minimum of 15 years of relevant experience in the pharmaceutical, academic and/or medical research environments Proven ability to lead and influence data-driven strategy planning and implementation A proactive and strategic thinker, with strong decision-making skills Proven ability to function effectively across a matrix organization with multiple&nbsp;stakeholders and constituents, with the ability and strength to focus a team to work towards its goals Demonstrated experience in successfully leading teams: running them effectively, efficiently and on target Ability to work cooperatively within a cross-functional, partially virtual team setting is critical, as are strong interpersonal communication skills Strong leadership and communication skills (including presentation skills) with success in influencing all levels cross-functionally Excellent business acumen and judgment with demonstrated ability to align teams to corporate strategy to achieve business and project objectives Strong staff management and mentoring experience and skills Highly collaborative with outstanding relationship building skills Arvinas will not be providing VISA sponsorship for this position now or in the future. You must have the ability to work without the need for current or future VISA sponsorship. The duties of this role are generally conducted in combination of company office and home office environments. Employees must be able, with or without accommodation, to lift/carry 15/30 pounds unassisted/assisted; work comfortable in a controlled environment with and around biological, infectious and hazardous materials; gown/degown PPE; use a computer; engage in communications via phone, video, and electronic messaging; engage in problem solving, analysis and dialogue; collaborate with others; maintain general availability during standard business hours. Education Ph.D., MD or MBA or advanced degree in biomedical sciences or one of the disciplines related to drug development Arvinas is proud to offer a competitive package of base and incentive compensation as well as a comprehensive benefits program designed to support the health, wellness and financial security of our employees and their families. Benefits include group medical, vision and dental coverage, group and supplemental life insurance, and much more. To learn more about Arvinas, please visit&nbsp;www.arvinas.com Arvinas is an equal opportunity employer. All qualified applicants will be considered for employment without regard to race, color, religion, sex, sexual orientation, gender identify, national origin, disability or protected veteran status.&nbsp; &nbsp;

Early Development Team Leader

Arvinas is a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. Arvinas uses its proprietary PROTAC® Discovery Engine platform to engineer proteolysis targeting chimeras, or PROTAC® targeted protein degraders, that are designed to harness the body’s own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Arvinas is currently progressing multiple investigational drugs through clinical development programs, including ARV-102, targeting LRRK2 for neurodegenerative diseases; ARV-806, targeting KRAS G12D for mutated cancers, including pancreatic, colorectal, and non-small cell lung cancers; ARV-393, targeting BCL6 for relapsed/refractory non-Hodgkin Lymphoma; ARV-027, targeting the polyglutamine-expanded androgen receptor, or polyQ-AR, in skeletal muscle; and vepdegestrant, targeting the estrogen receptor for patients with locally advanced or metastatic ER+/HER2- breast cancer. On August 8th 2025, the U.S. Food and Drug Administration (FDA) &nbsp;accepted the New Drug Application (NDA) for vepdegestrant- an investigational, orally bioavailable PROTAC estrogen receptor degrader- for its use as a monotherapy in the treatment of adults with estrogen receptor–positive (ER+), human epidermal growth factor receptor 2–negative (HER2-), ESR1-mutated advanced or metastatic breast cancer previously treated with endocrine-based therapy. In September 2025, Arvinas and Pfizer announced their plan to jointly select a third party for the out-licensing and commercialization of vepdegestrant. In April 2024, Arvinas entered into a transaction with Novartis, including a global license agreement for the development and commercialization of the clinical stage PROTAC® androgen receptor protein degrader ARV-766 for the treatment of prostate cancer. The transaction closed in May 2024. #TeamArvinas is made up of passionate and curious employees, whose diverse thoughts and perspectives are highly valued. Arvinas employees embrace the freedom to pursue innovation, think creatively, and give back. They are driven by the company’s values and mission – to improve the lives of patients with serious diseases by pioneering therapies created with our revolutionary PROTAC® protein degradation platform. We’re really excited about the work we’re doing inside and outside of Arvinas, and think you will be, too. But don’t just take our word for it –&nbsp;learn more about life at Arvinas and what employees have to say. Arvinas is headquartered in New Haven, Connecticut. For more information about Arvinas, visit www.arvinas.com&nbsp;and connect on&nbsp;LinkedIn&nbsp;and&nbsp;X. Position Summary Arvinas is looking for an experienced Senior Medical Director with the passion and creativity to develop great medicines for neuromuscular and neurodegenerative diseases. The ideal candidate is a physician with experience in global drug development and filing, who is enthusiastic about applying their knowledge to improve the lives of patients with neurological diseases. This individual has excellent management and leadership capabilities and is motivated to participate in and lead an innovative drug development team. Reporting to the Executive Medical Director of Clinical Research, Neuroscience, the Senior Medical Director will be primarily responsible for the development, oversight, and execution of clinical research and development programs, including pivotal trials and filing activities. This position will serve as a key liaison between company and clinical investigators and establish credible relationships with opinion leaders, regulatory officials and other key stakeholders and partners. The successful candidate will be ready for a career defining experience and have the passion to drive several therapeutics for serious debilitating diseases to final approval. This role can be located at our headquarters in New Haven, CT or work with a hybrid or remote work arrangement from a location within the U.S. Principal Responsibilities Key responsibilities of this role include, but are not limited to: Partner with discovery and biology leadership and provide clinical input and guidance to develop the neuroscience corporate strategy. Design Phase I/II/III research trials targeting neurologic diseases, requiring expertise and stewardship in the areas of CNS/Neurology Monitor the safety of patients enrolled in clinical studies Provide medical and scientific input in review of clinical data, patient medical safety data, and laboratory values, maintaining an ongoing assessment of the safety profile, and efficacy data, as appropriate. Work closely with all functions of the organization and external partners to manage trial execution and investigators’ engagement. Collaborate in developing global regulatory plans and play a key role in regulatory meetings in partnership with regulatory affairs. Identify, develop, and maintain relationships with external experts to better understand the candidate drug’s effects and gain strategic insights to strengthen the program. Provide clinical assessments of potential in-licensing assets, identifying novel therapeutics opportunities as well as critical study design and execution challenges. Lead the interpretation and summary of clinical trial data, including the preparation of study reports, integrated summaries, and clinical portions of package inserts and other product labeling. Provide input on and review of various reports, applications, and publications Ensure consistent practices with the highest ethical standards in compliance with internal SOPs, local regulations, and laws. Additional Responsibilities, including but not limited to: Participate in the selection of clinical investigators Provide guidance to study investigators Provide medical support to Clinical Operations in the oversight of contract research organizations Provide medical and scientific input on clinical data, patient medical safety data, and laboratory values, maintaining an ongoing assessment of the safety profile, and efficacy data, as appropriate. Contribute to the overall strategy for drug development Collaborate on the preparation and submission of IND, CTA, and NDA documents, and safety reports. Support the clinical aspects of interactions with regulatory agencies worldwide Participate in the planning, writing, and review of Clinical Study Reports, regulatory updates, and submissions. Analyze and interpret study data for abstracts or publication as required. Assist in the evaluation of scientific opportunities by contributing to due diligence activities, including critical assessment of clinical and translational data. Provide medical expertise to support corporate partnering and business development efforts, including active participation in partnership committees and cross-functional task groups. Collaborate with senior leadership and cross-functional teams to inform overall company strategy and contribute to the identification, evaluation, and in-licensing of new programs. Work with the financial group as needed to assist with the production of budgets and timelines for the clinical development team. Ensure that medical activities in clinical trials are conducted in compliance with Good Clinical Practice standards.&nbsp; Qualifications A minimum of 5 years (7+ years strongly preferred) of biotech/pharma experience in neurological disease clinical drug development Experience across multiple stages of clinical development, from IND to NDA / BLA. Global clinical development experience is required, and global filing experience is preferred. Technical (Medical and Scientific) experience evaluating targets/agents for in-licensing or internal development. Experience supervising physicians and/or scientific staff in a management or team leader capacity is highly desirable. Excellent interpersonal and public speaking skills are required for this high visibility position. Demonstrated ability to work in a matrix environment with cross-functional teams. Must be legally authorized to work in the US without the need for employer sponsorship now or at any time in the future. The duties of this role are generally conducted in a home office environment. Employees must be able, with or without accommodation, to use a computer; engage in communications via phone, video, and electronic messaging; engage in problem solving and non-linear thought, analysis, and dialogue; collaborate with others; maintain general availability during standard business hours. Education M.D. or equivalent degree is required. Formal training in Neurology and professional board certification are highly preferred. INSERT JOB DESCRIPTION HERE Arvinas is proud to offer a competitive package of base and incentive compensation as well as a comprehensive benefits program designed to support the health, wellness and financial security of our employees and their families. Benefits include group medical, vision and dental coverage, group and supplemental life insurance, and much more. To learn more about Arvinas, please visit www.arvinas.com Arvinas is an equal opportunity employer. All qualified applicants will be considered for employment without regard to race, color, religion, sex, sexual orientation, gender identify, national origin, disability or protected veteran status.&nbsp; &nbsp;

Senior Medical Director Clinical Development Neuroscience

Arvinas is a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. Arvinas uses its proprietary PROTAC Discovery Engine platform to engineer proteolysis targeting chimeras, or PROTAC targeted protein degraders, that are designed to harness the body’s own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Arvinas is currently progressing multiple investigational drugs through clinical development programs, including ARV-102, targeting LRRK2 for neurodegenerative diseases; ARV-806, targeting KRAS G12D for mutated cancers, including pancreatic, colorectal, and non-small cell lung cancers; ARV-393, targeting BCL6 for relapsed/refractory non-Hodgkin Lymphoma; ARV-027, targeting the polyglutamine-expanded androgen receptor, or polyQ-AR, in skeletal muscle; and vepdegestrant, targeting the estrogen receptor for patients with locally advanced or metastatic ER+/HER2- breast cancer. On August 8th 2025, the U.S. Food and Drug Administration (FDA) &nbsp;accepted the New Drug Application (NDA) for vepdegestrant- an investigational, orally bioavailable PROTAC estrogen receptor degrader- for its use as a monotherapy in the treatment of adults with estrogen receptor–positive (ER+), human epidermal growth factor receptor 2–negative (HER2-), ESR1-mutated advanced or metastatic breast cancer previously treated with endocrine-based therapy. In September 2025, Arvinas and Pfizer announced their plan to jointly select a third party for the out-licensing and commercialization of vepdegestrant. In April 2024, Arvinas entered into a transaction with Novartis, including a global license agreement for the development and commercialization of the clinical stage PROTAC androgen receptor protein degrader ARV-766 for the treatment of prostate cancer. The transaction closed in May 2024. #TeamArvinas is made up of passionate and curious employees, whose diverse thoughts and perspectives are highly valued. Arvinas employees embrace the freedom to pursue innovation, think creatively, and give back. They are driven by the company’s values and mission – to improve the lives of patients with serious diseases by pioneering therapies created with our revolutionary PROTAC protein degradation platform. We’re really excited about the work we’re doing inside and outside of Arvinas, and think you will be, too. But don’t just take our word for it – learn more about life at Arvinas and what employees have to say. &nbsp; Arvinas is headquartered in New Haven, Connecticut. For more information about Arvinas, please visit www.arvinas.com and connect on&nbsp;LinkedIn&nbsp;and&nbsp;X. &nbsp; Position Summary&nbsp; We have an exciting opportunity for an experienced scientist to join our biochemical and biophysical assay team in Platform Biology. The selected candidate will participate in assay design, implementation, and data quality control across our programs in ligand discovery and targeted protein degradation. Ideally, the candidate will be experienced in Surface Plasmon Resonance (SPR) and have broad expertise covering various biochemical and biophysical assays and instrumentation. This position will drive assay development, execution and provide the key, critical data necessary to advance programs towards targeted protein degradation in highly disease relevant projects to help human health. This position reports to the Senior Research Investigator, Degrader Mechanisms Group in our Platform Biology department and will be located at our headquarters in New Haven, CT. &nbsp; Principal Responsibilities Key responsibilities of this role include, but are not limited to: Biophysical assay design and execution across different modalities, with a focus on SPR and including TSA, DSF, and MST. Evaluation and implementation of cellular ligand binding and characterization techniques (such as BRET, NanoBRET and other high-throughput cellular target engagement assays) Biochemical assay design, assay development and execution across different plate-based modalities, such as TR-FRET, FP, and alphaLISA. Mechanism of action studies of ligand binding and degrader characterization utilizing cellular and biochemical assays. Manage CRO outsourcing of biochemical and biophysical assays such as ASMS, as necessary. Data capture, database upload, and presentation of assay development and trouble-shooting data in a clear manner in a group meeting setting. Partner with diverse project teams in complex scheduling of work and generation of data in support of drug discovery and development programs. Troubleshoot through technical and scientific challenges in order to deliver critical data. Serve as Platform Lead scientist for assigned projects. Communicate and coordinate Platform activities, and be primary point of contact for biochemical and biophysical needs for assigned projects across wider project teams Apply excellent organizational and prioritization skills; analyze data using strong background in biochemistry and biophysics and troubleshoot through technical and scientific challenges in order to deliver critical data. Organize experimental results to be shared with project teams; maintain clear experimental records using ELN (electronic lab notebook). (List bullet points of key responsibilities) &nbsp; Qualifications Skilled, motivated and productive bench scientist with excellent communication and organizational skills who works effectively in a dynamic team setting. Strong background in protein biochemistry and biophysics; expertise in protein-ligand interactions, induced proximity approaches, or cellular ligand interactions are pluses. Demonstrated experience in experimental design, execution, and data analysis for protein-protein and protein-ligand interactions using biophysical and/or biochemical techniques; experience with cellular ligand target engagement techniques is a plus. Demonstrated experience with SPR; additional experience with plate-based assay formats and instrumentation across biochemical and biophysical platforms including TR-FRET, FP, alphaLISA, ASMS, and TSA, are pluses. Exhibited proficiency in problem solving and analytical thinking skills Experience outsourcing CRO work and managing projects and timelines. Arvinas will not be providing VISA sponsorship for this position now or in the future. You must have the ability to work without a need for a current or future VISA sponsorship. The duties of this role are generally conducted in a lab environment. Employees must be able, with or without an accommodation to lift/carry 15/30 pounds unassisted/assisted; work comfortable in a controlled environment with and around biological, infectious and hazardous materials; gown/degown PPE; use a computer; engage in communications via phone, video, and electronic messaging; engage in problem solving, analysis and dialogue; collaborate with others; maintain general availability during standard business hours. &nbsp; &nbsp; Education S. with 7+ years of pharma/biotech or academic experience, or Ph.D with 2+ years of pharma/biotech or academic experience, with a focus on biophysical and/or biochemical assay execution. Background in protein-protein and protein-ligand interactions and in drug discovery. Background in the protein degradation, induced proximity, and ubiquitin proteasome system are pluses. Additional training in complimentary biophysical, biochemical, and targeted protein degradation techniques will be provided as needed. &nbsp; Arvinas is proud to offer a competitive package of base and incentive compensation as well as a comprehensive benefits program designed to support the health, wellness and financial security of our employees and their families. Benefits include group medical, vision and dental coverage, group and supplemental life insurance, and much more. To learn more about Arvinas, please visit www.arvinas.com Arvinas is an equal opportunity employer. All qualified applicants will be considered for employment without regard to race, color, religion, sex, sexual orientation, gender identify, national origin, disability or protected veteran status.&nbsp; &nbsp;

Senior Research Scientist Platform Biology

Arvinas is a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. Arvinas uses its proprietary PROTAC Discovery Engine platform to engineer proteolysis targeting chimeras, or PROTAC targeted protein degraders, that are designed to harness the body’s own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Arvinas is currently progressing multiple investigational drugs through clinical development programs, including ARV-102, targeting LRRK2 for neurodegenerative diseases; ARV-806, targeting KRAS G12D for mutated cancers, including pancreatic, colorectal, and non-small cell lung cancers; ARV-393, targeting BCL6 for relapsed/refractory non-Hodgkin Lymphoma; ARV-027, targeting the polyglutamine-expanded androgen receptor, or polyQ-AR, in skeletal muscle; and vepdegestrant, targeting the estrogen receptor for patients with locally advanced or metastatic ER+/HER2- breast cancer. On August 8th 2025, the U.S. Food and Drug Administration (FDA) &nbsp;accepted the New Drug Application (NDA) for vepdegestrant- an investigational, orally bioavailable PROTAC estrogen receptor degrader- for its use as a monotherapy in the treatment of adults with estrogen receptor–positive (ER+), human epidermal growth factor receptor 2–negative (HER2-), ESR1-mutated advanced or metastatic breast cancer previously treated with endocrine-based therapy. In September 2025, Arvinas and Pfizer announced their plan to jointly select a third party for the out-licensing and commercialization of vepdegestrant. In April 2024, Arvinas entered into a transaction with Novartis, including a global license agreement for the development and commercialization of the clinical stage PROTAC androgen receptor protein degrader ARV-766 for the treatment of prostate cancer. The transaction closed in May 2024. #TeamArvinas is made up of passionate and curious employees, whose diverse thoughts and perspectives are highly valued. Arvinas employees embrace the freedom to pursue innovation, think creatively, and give back. They are driven by the company’s values and mission – to improve the lives of patients with serious diseases by pioneering therapies created with our revolutionary PROTAC protein degradation platform. We’re really excited about the work we’re doing inside and outside of Arvinas, and think you will be, too. But don’t just take our word for it – learn more about life at Arvinas and what employees have to say. &nbsp; Arvinas is headquartered in New Haven, Connecticut. For more information about Arvinas, please visit www.arvinas.com and connect on&nbsp;LinkedIn&nbsp;and&nbsp;X. &nbsp; Position Summary&nbsp; Arvinas is seeking an experienced Desktop Support Specialist to perform Level 2 day-to-day escalation activities. &nbsp;&nbsp;This person will be responsible for Deskside Support, Software Distribution, Asset and Desktop management, Executive Support, Event Support, and Audio Visual Support for Arvinas. This position reports to the Sr. Manager, IT Service Delivery Lead, and will be located at our headquarters in New Haven, CT. &nbsp; Principal Responsibilities Key responsibilities of this role include, but are not limited to: Oversee 100% of the requests, incidents, and problems. Manage and coordinate urgent and complicated support issues. Demonstrated ability and passion for the delivery of high-quality end-user support experiences. Thorough understanding and knowledge of desktop support best practices in a research pharmaceutical setting. Ability to prioritize and act in high-pressure situations. Demonstrated customer service, interpersonal and technical skills in communication, both written and verbal at all levels of an organization. Demonstrated experience with IT Service Desk systems and tools, ideally BMC Footprints Service Management. Executive and Audio-Visual support functions required with a track record of rapid issue resolution, and support experience for hybrid meetings and events. ITIL Knowledge, preferably certification. Ensure that all processes used by the service desk are thoroughly documented, consistently audited, and regularly improved. Performs other duties as assigned. &nbsp; &nbsp; &nbsp; Qualifications Very strong business analysis skills Very strong technical troubleshooting and problem-solving abilities Excellent task management and prioritization skills Excellent written and verbal communication skills Knowledge of the following is highly desired: Entire Microsoft Office365 Stack including Active Directory, Azure Active Directory, Office Licensing. Familiarity with ITIL 4 Framework Precise knowledge of Asset Management including physical assets and software licenses The duties of this role are generally conducted in a combination of company office and lab environment. Employees must be able, with or without an accommodation to lift/carry 15/30 pounds unassisted/assisted; work comfortable in a controlled environment with and around biological, infectious and hazardous materials; gown/degown PPE; use a computer; engage in communications via phone, video, and electronic messaging; engage in problem solving, analysis and dialogue; collaborate with others; maintain general availability during standard business hours. Arvinas will not be providing VISA sponsorship for this position. You must have the ability to work without a need for a current or future VISA sponsorship &nbsp; &nbsp; Education A degree or certificate in Computer Science, Computer Information Management Systems or other related IT discipline desired OR Proven 3-5 years experience in a support services role and must possess analytical, problem-solving, and communication skills &nbsp; Experience 4 + years’ experience in IT, with the desired candidate having experience in life sciences Experience providing IT application support and maintenance Arvinas is proud to offer a competitive package of base and incentive compensation as well as a comprehensive benefits program designed to support the health, wellness and financial security of our employees and their families. Benefits include group medical, vision and dental coverage, group and supplemental life insurance, and much more. To learn more about Arvinas, please visit www.arvinas.com Arvinas is an equal opportunity employer. All qualified applicants will be considered for employment without regard to race, color, religion, sex, sexual orientation, gender identify, national origin, disability or protected veteran status.&nbsp; &nbsp;

Desktop Support Specialist

Arvinas is a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. Arvinas uses its proprietary PROTAC Discovery Engine platform to engineer proteolysis targeting chimeras, or PROTAC targeted protein degraders, that are designed to harness the body’s own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Arvinas is currently progressing multiple investigational drugs through clinical development programs, including ARV-102, targeting LRRK2 for neurodegenerative diseases; ARV-806, targeting KRAS G12D for mutated cancers, including pancreatic, colorectal, and non-small cell lung cancers; ARV-393, targeting BCL6 for relapsed/refractory non-Hodgkin Lymphoma; ARV-027, targeting the polyglutamine-expanded androgen receptor, or polyQ-AR, in skeletal muscle; and vepdegestrant, targeting the estrogen receptor for patients with locally advanced or metastatic ER+/HER2- breast cancer. On August 8th 2025, the U.S. Food and Drug Administration (FDA) &nbsp;accepted the New Drug Application (NDA) for vepdegestrant- an investigational, orally bioavailable PROTAC estrogen receptor degrader- for its use as a monotherapy in the treatment of adults with estrogen receptor–positive (ER+), human epidermal growth factor receptor 2–negative (HER2-), ESR1-mutated advanced or metastatic breast cancer previously treated with endocrine-based therapy. In September 2025, Arvinas and Pfizer announced their plan to jointly select a third party for the out-licensing and commercialization of vepdegestrant. In April 2024, Arvinas entered into a transaction with Novartis, including a global license agreement for the development and commercialization of the clinical stage PROTAC androgen receptor protein degrader ARV-766 for the treatment of prostate cancer. The transaction closed in May 2024. #TeamArvinas is made up of passionate and curious employees, whose diverse thoughts and perspectives are highly valued. Arvinas employees embrace the freedom to pursue innovation, think creatively, and give back. They are driven by the company’s values and mission – to improve the lives of patients with serious diseases by pioneering therapies created with our revolutionary PROTAC protein degradation platform. We’re really excited about the work we’re doing inside and outside of Arvinas, and think you will be, too. But don’t just take our word for it – learn more about life at Arvinas and what employees have to say. &nbsp; Arvinas is headquartered in New Haven, Connecticut. For more information about Arvinas, please visit www.arvinas.com and connect on&nbsp;LinkedIn&nbsp;and&nbsp;X. &nbsp; Position Summary This is a senior executive role responsible for all CMC activities from preclinical to product launch and leadership of an established Technical Operations group. The role has oversight of drug substance (API) and drug product (DP) development and production for preclinical, clinical, and commercial requirements. &nbsp;It is responsible for development, scale-up, analytical testing of API and DP. The role has oversight of identification, on-boarding, and management of external vendors and CMO’s. The incumbent is responsible for representing Arvinas CMC function in meetings with regulatory authorities and review of CMC documentation consistent with relevant regulations and guidelines. The role is responsible for higher level integration of Technical Operations activities with key stake holders such as discovery chemistry, quality, clinical, and regulatory groups. This role is a key member of the Executive Committee Portfolio team, Development Governance, and reports to the Chief Financial Officer. The role can be remote, hybrid, or located at our headquarters in New Haven, CT. Principal Responsibilities Key responsibilities of this role include, but are not limited to: Leadership of the Technical Operations group which incorporates exploratory pharmaceutics, API, DP and Analytical Development, supply chain planning, and CMC authoring. Ensuring product supply from pre-clinical development through clinical to commercialization. Providing strategic direction and planning of the technical development and manufacturing of clinical/commercial products with attention to quality, robust and reliable supply, cost-effectiveness and efficient scaling. Continuing a Technical Operations approach that establishes fast-to-clinic and fast-to-commercial as primary objectives in support of the Arvinas pipeline. Responsible for establishing and managing the relationships with contract manufacturers, to assure that commercial and clinical production needs are met cost-effectively and in compliance with all GMP regulations and regulatory standards. Establishing partnerships with Discovery, Clinical, Quality, Regulatory and Commercial to ensure a rapid and successful progression of assets to the commercial market. Developing and managing annual expense budgets with accurate forecasting based on strategic objectives and prudent decisions regarding expenditures. Interfacing with senior management to reach decisions that provide best opportunity for organizational success. Leading the compilation and review of technical sections for Module 2/3 in INDs, IMPDs, NDAs, and MAAs. Acting as a key executive interface with FDA and EMA for quality sections in INDs, NDAs, IMPDs, and MAAs Building a high performing team ensuring that organizational depth is maintained for all key positions. &nbsp; Qualifications A minimum of 20 years experience working within areas of medicinal chemistry, chemical development, pharmaceutical development, and/or analytical development. At least 10 years’ experience in a small/medium biotech environment with substantial CMC area leadership responsibilities. &nbsp; Expertise in small molecule synthesis and process development, pre-formulation/formulation development, and analytical development of the same is required. &nbsp; Expert-level understanding of API/DP process development and scale-up. &nbsp; Expert-level understanding of analytical methods and instrumentation used to characterize reactions, material properties, APIs, and drug products. &nbsp; Experience with and understanding Design of Experiments (DOE), Quality by Design (QbD), Process Analytical Technology (PAT), scale up, formulation and process technologies &nbsp; Demonstrated success in advancing a molecule from drug discovery to commercialization. &nbsp; Demonstrated success in drafting module 2/3 sections of INDs, IMPDs, NDAs, and MAAs. &nbsp; Extensive working knowledge of GxP practices, ICH guidelines, and other regulatory practices as applied to phase-appropriate applications. &nbsp; Strong leadership and management abilities. &nbsp; Critical analysis and strategic thought embedded within exceptional decision-making abilities. &nbsp; Excellent communication, problem-solving and organizational skills applicable in a cross-functional team environment. &nbsp; Extensive knowledge of scientific literature and of emerging research areas of pharmaceutical science. &nbsp; Arvinas will not be providing VISA sponsorship for this position. You must have the ability to work without a need for a current or future VISA sponsorship. &nbsp; The duties of this role are generally conducted in a combination of office, lab and home office environments. Employees must be able, with or without an accommodation to lift/carry 15/30 pounds unassisted/assisted; work comfortable in a controlled environment with and around biological, infectious and hazardous materials; gown/degown PPE; use a computer; engage in communications via phone, video, and electronic messaging; engage in problem solving, analysis and dialogue; collaborate with others; maintain general availability during standard business hours. &nbsp; EDUCATION Ph.D. in organic/medicinal chemistry or pharmaceutics. A combination of relevant education, demonstrated subject matter expertise, and applicable job experience may be considered in lieu of the degree. &nbsp; #LI-Remote Arvinas is proud to offer a competitive package of base and incentive compensation as well as a comprehensive benefits program designed to support the health, wellness and financial security of our employees and their families. Benefits include group medical, vision and dental coverage, group and supplemental life insurance, and much more. To learn more about Arvinas, please visit www.arvinas.com Arvinas is an equal opportunity employer. All qualified applicants will be considered for employment without regard to race, color, religion, sex, sexual orientation, gender identify, national origin, disability or protected veteran status.&nbsp; &nbsp; &nbsp;

Vice President, Technical Operations

Arvinas is a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. Arvinas uses its proprietary PROTAC Discovery Engine platform to engineer proteolysis targeting chimeras, or PROTAC targeted protein degraders, that are designed to harness the body’s own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Arvinas is currently progressing multiple investigational drugs through clinical development programs, including ARV-102, targeting LRRK2 for neurodegenerative diseases; ARV-806, targeting KRAS G12D for mutated cancers, including pancreatic, colorectal, and non-small cell lung cancers; ARV-393, targeting BCL6 for relapsed/refractory non-Hodgkin Lymphoma; ARV-027, targeting the polyglutamine-expanded androgen receptor, or polyQ-AR, in skeletal muscle; and vepdegestrant, targeting the estrogen receptor for patients with locally advanced or metastatic ER+/HER2- breast cancer. On August 8th 2025, the U.S. Food and Drug Administration (FDA) &nbsp;accepted the New Drug Application (NDA) for vepdegestrant- an investigational, orally bioavailable PROTAC estrogen receptor degrader- for its use as a monotherapy in the treatment of adults with estrogen receptor–positive (ER+), human epidermal growth factor receptor 2–negative (HER2-), ESR1-mutated advanced or metastatic breast cancer previously treated with endocrine-based therapy. In September 2025, Arvinas and Pfizer announced their plan to jointly select a third party for the out-licensing and commercialization of vepdegestrant. In April 2024, Arvinas entered into a transaction with Novartis, including a global license agreement for the development and commercialization of the clinical stage PROTAC androgen receptor protein degrader ARV-766 for the treatment of prostate cancer. The transaction closed in May 2024. #TeamArvinas is made up of passionate and curious employees, whose diverse thoughts and perspectives are highly valued. Arvinas employees embrace the freedom to pursue innovation, think creatively, and give back. They are driven by the company’s values and mission – to improve the lives of patients with serious diseases by pioneering therapies created with our revolutionary PROTAC protein degradation platform. We’re really excited about the work we’re doing inside and outside of Arvinas, and think you will be, too. But don’t just take our word for it – learn more about life at Arvinas and what employees have to say. &nbsp; Arvinas is headquartered in New Haven, Connecticut. For more information about Arvinas, please visit www.arvinas.com and connect on&nbsp;LinkedIn&nbsp;and&nbsp;X. &nbsp; Position Summary We have an exciting opening for an experienced DMPK scientist. The incumbent will contribute as a DMPK scientist on project teams from drug discovery through all stages of drug development, with a scientific background on key aspects of DMPK science, including but not limited to in vitro and in vivo ADME, animal PK, toxicokinetics, drug metabolism, DME- and transporter-based DDI, &nbsp;14C-ADME studies, QWBA, human PK prediction. &nbsp;&nbsp;&nbsp; This position reports to the Head of Nonclinical Sciences and may be based at our headquarter location in New Haven, CT or a remote role based within the U.S. &nbsp; Principal Responsibilities Key responsibilities of this role include, but are not limited to: Serve as a project DMPK scientist and advise discovery teams on strategies for early ADMET profiling up to the selection of lead candidate into preclinical development. Represent DMPK function on company-wide development teams to support the advancement of preclinical and clinical development assets. Contribute to the in vitro DDI and other in vitro/in vivo DMPK assessment for individual preclinical drug candidates and ensure timely availability of key data as part of the IND enabling activities. Recommend stage appropriate clinical DDI strategy to the clinical pharmacology function.&nbsp; Contribute to outsource of DMPK studies and ensure timely and high quality conduct of in vitro and in vivo ADMET studies. Partner with key CROs to develop and customize ADMET assays to support PROTAC drug discovery and development. Contribute to the preparation of DMPK component of regulatory documents such as IND, IB, or other documents. Stay up to date with the scientific advance and regulatory landscape for DMPK science in drug discovery and development &nbsp; Qualifications In-depth knowledge or expertise on one or several aspects of DMPK science in drug discovery and/or development, such as biotransformation, bioanalysis, pharmacokinetics, toxicokinetics, DME- and transporter-based drug-drug interaction, PBPK or PK/PD modeling, human PK prediction. General knowledge of drug discovery and development process. Experience in representing DMPK function on discovery and development teams. Ability to integrate DMPK knowledge of individual drugs and prepare DMPK components of regulatory documents. Hands-on experience and proficiency in PK analysis with PK or modeling software such as Phoenix. Knowledge of relevant regulatory guidance in areas such as drug-drug interaction, bioanalysis, and GLP. Arvinas will not be providing VISA sponsorship for this position. You must have the ability to work without a need for a current or future VISA sponsorship. The duties of this role are generally conducted in a combination of lab and home office environments. Employees must be able, with or without an accommodation to lift/carry 15/30 pounds unassisted/assisted; work comfortable in a controlled environment with and around biological, infectious and hazardous materials; gown/degown PPE; use a computer; engage in communications via phone, video, and electronic messaging; engage in problem solving, analysis and dialogue; collaborate with others; maintain general availability during standard business hours. Education Ph.D. in pharmaceutical science, chemistry, biochemistry, or related scientific discipline with ten-plus years of relevant experience in DMPK in the biopharmaceutical industry or CROs supporting pharmaceutical development, preferably with a focus on small molecules. Direct experience with PROTAC, molecular glue, or ADC highly desirable. &nbsp; Arvinas is proud to offer a competitive package of base and incentive compensation as well as a comprehensive benefits program designed to support the health, wellness and financial security of our employees and their families. Benefits include group medical, vision and dental coverage, group and supplemental life insurance, and much more. To learn more about Arvinas, please visit&nbsp;www.arvinas.com Arvinas is an equal opportunity employer. All qualified applicants will be considered for employment without regard to race, color, religion, sex, sexual orientation, gender identify, national origin, disability or protected veteran status.&nbsp; &nbsp;

DMPK Scientist

Arvinas is a biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. Arvinas uses its proprietary PROTAC Discovery Engine platform to engineer PROteolysis TArgeting Chimeras, or PROTACs, that are designed to harness the body’s own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. This differentiated approach has enabled Arvinas to build a broad pipeline of investigational therapies across oncology and neurodegenerative diseases, including ARV-102, targeting LRRK2 for neurodegenerative diseases; ARV-806, targeting KRAS G12D for mutated cancers, including pancreatic, colorectal, and non-small cell lung cancers; ARV-393, targeting BCL6 for relapsed/refractory non-Hodgkin Lymphoma; ARV-027, targeting the polyglutamine-expanded androgen receptor, or polyQ-AR, in skeletal muscle for spinal bulbar muscular atrophy; and vepdegestrant, targeting the estrogen receptor for patients with locally advanced or metastatic ER+/HER2- breast cancer. Building on its leadership in targeted protein degradation, Arvinas achieved a major milestone in May 2026 with the first-ever U.S. Food and Drug Administration (FDA) approval of a PROTAC protein degrader therapy. The approval marked a significant advancement for the field and demonstrated the therapeutic potential of targeted protein degradation as a novel treatment modality. This PROTAC has been out-licensed for commercialization and further development. #TeamArvinas is made up of passionate and curious employees, whose diverse thoughts and perspectives are highly valued. Arvinas employees embrace the freedom to pursue innovation, think creatively, and give back. They are driven by the company’s values and mission – to improve the lives of patients with serious diseases by pioneering therapies created with our revolutionary PROTAC protein degradation platform. We’re really excited about the work we’re doing inside and outside of Arvinas, and think you will be, too. But don’t just take our word for it –&nbsp;learn more about life at Arvinas and what employees have to say. Arvinas is headquartered in New Haven, Connecticut. For more information about Arvinas, visit www.arvinas.com&nbsp;and connect on&nbsp;LinkedIn&nbsp;and&nbsp;X. Position Summary We are&nbsp;seeking&nbsp;an experienced and highly motivated&nbsp;Research Scientist/Senior&nbsp;Research&nbsp;Scientist to&nbsp;lead and execute cellular and tissue-based target engagement&nbsp;studies&nbsp;of small molecule ligands and targeted protein degraders (e.g., PROTACs).&nbsp;This role will play a central part in advancing&nbsp;degrader molecule&nbsp;discovery&nbsp;programs&nbsp;for CNS indications&nbsp;by developing, implementing, and scaling quantitative assays to assess compound binding, ternary complex formation, and functional engagement in physiologically relevant systems, including human-derived tissues and cellular models.&nbsp;This is an opportunity to help&nbsp;establish&nbsp;and scale target engagement capabilities for CNS degrader discovery, directly influencing compound optimization and translational decision-making across neuroscience programs.&nbsp; &nbsp; This position reports to our Director&nbsp;of Neuroscience&nbsp;and will be&nbsp;located&nbsp;at our headquarters in New Haven, CT.&nbsp; &nbsp; Principal Responsibilities Key responsibilities of this role include, but are not limited to:&nbsp; Design, develop,&nbsp;optimize, and&nbsp;validate&nbsp;cellular and biochemical assays to measure target engagement and degradation driven by small molecules and&nbsp;targeted protein degraders.&nbsp;&nbsp; Design and execute fit-for-purpose studies to evaluate binary target engagement and ternary complex formation in cellular and tissue-based systems, using technologies such as TR-FRET,&nbsp;NanoBRET,&nbsp;AlphaLISA, luciferase-based assays, biotinylated probes, photoaffinity labeling, and related probe-based or proximity-based approaches.&nbsp; Apply&nbsp;appropriate controls, counter-screens, and orthogonal readouts to evaluate assay specificity, reproducibility, robustness, and potential artifacts.&nbsp; Adapt assays for medium- to high-throughput screening to support compound profiling, degrader optimization, and screening campaigns.&nbsp;&nbsp; Collaborate cross-functionally with medicinal chemistry&nbsp;and platform biology&nbsp;teams to guide optimization of both ligands and degraders based on engagement and degradation data.&nbsp;&nbsp; Analyze, interpret, and integrate complex datasets across multiple assay platforms to guide data-driven project decisions.&nbsp;&nbsp; Organize experimental results to be shared with project teams;&nbsp;maintain&nbsp;clear experimental records using ELN (electronic lab notebook).&nbsp;&nbsp; Seek&nbsp;to be an impactful and valued member of the team who drives data-driven&nbsp;decisions and stays&nbsp;current with emerging technologies in targeted protein degradation and neurodegeneration research.&nbsp; &nbsp; Qualifications Deep hands-on experience&nbsp;(3+ years)&nbsp;developing and executing cellular or tissue-based assays for small-molecule target engagement, degradation, or specificity assessment.&nbsp; Demonstrated&nbsp;expertise&nbsp;with plate-based assay development, including assay design, optimization, troubleshooting, validation, control&nbsp;selection, reproducibility assessment, and artifact identification.&nbsp;&nbsp; Experience using probe-based or proximity-based strategies, such as biotinylated probes, photoaffinity labeling,&nbsp;NanoBRET, TR-FRET,&nbsp;AlphaLISA, luciferase-based assays, or related approaches.&nbsp;&nbsp; Experience adapting assays for robustness, scalability, miniaturization, and multi-well plate formats to support compound profiling or screening workflows.&nbsp;&nbsp; Strong data analysis skills using tools such as Prism, Gene Data, Python, or R.&nbsp;&nbsp; Track record&nbsp;of scientific contributions (publications, patents, or program impact) and cross-functional collaboration skills.&nbsp; Background in neurodegenerative disease biology (e.g., tau, alpha-synuclein, TDP-43, amyloid-beta)&nbsp;strongly&nbsp;desired.&nbsp;&nbsp; Experience working with rodent and human-derived tissues (e.g., post-mortem brain)&nbsp;a plus.&nbsp; Familiarity with biophysical binding assays (SPR, MST, FP) and orthogonal validation strategies&nbsp;a plus.&nbsp;&nbsp; Arvinas will not be providing VISA sponsorship for this position now or in the future. You must have the ability to work without a need for current or future VISA sponsorship. The duties of this role are generally conducted in a lab environment. Employees must be able, with or without an accommodation to lift/carry 15/30 pounds unassisted/assisted; work comfortable in a controlled environment with and around biological, infectious and hazardous materials; gown/degown PPE; use a computer; engage in communications via phone, video, and electronic messaging; engage in problem solving, analysis and dialogue; collaborate with others; maintain general availability during standard business hours. &nbsp; EDUCATION BS/MS&nbsp;with&nbsp;8+ or&nbsp;Ph.D.&nbsp;with&nbsp;3+&nbsp;years of&nbsp;pharma/biotech/academic&nbsp;laboratory experience.&nbsp; Background&nbsp;in protein-protein&nbsp;or&nbsp;protein-ligand interactions is&nbsp;required.&nbsp; #LI-Remote Arvinas is proud to offer a competitive package of base and incentive compensation as well as a comprehensive benefits program designed to support the health, wellness and financial security of our employees and their families. Benefits include group medical, vision and dental coverage, group and supplemental life insurance, and much more. To learn more about Arvinas, please visit www.arvinas.com Arvinas is an equal opportunity employer. All qualified applicants will be considered for employment without regard to race, color, religion, sex, sexual orientation, gender identify, national origin, disability or protected veteran status.&nbsp; &nbsp;

Senior Research Scientist - Neuroscience

Arvinas is a biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. Arvinas uses its proprietary PROTAC Discovery Engine platform to engineer PROteolysis TArgeting Chimeras, or PROTACs, that are designed to harness the body’s own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins.
This differentiated approach has enabled Arvinas to build a broad pipeline of investigational therapies across oncology and neurodegenerative diseases, including ARV-102, targeting LRRK2 for neurodegenerative diseases; ARV-806, targeting KRAS G12D for mutated cancers, including pancreatic, colorectal, and non-small cell lung cancers; ARV-393, targeting BCL6 for relapsed/refractory non-Hodgkin Lymphoma; ARV-027, targeting the polyglutamine-expanded androgen receptor, or polyQ-AR, in skeletal muscle for spinal bulbar muscular atrophy; and vepdegestrant, targeting the estrogen receptor for patients with locally advanced or metastatic ER+/HER2- breast cancer.
Building on its leadership in targeted protein degradation, Arvinas achieved a major milestone in May 2026 with the first-ever U.S. Food and Drug Administration (FDA) approval of a PROTAC protein degrader therapy. The approval marked a significant advancement for the field and demonstrated the therapeutic potential of targeted protein degradation as a novel treatment modality. This PROTAC has been out-licensed for commercialization and further development.
#TeamArvinas is made up of passionate and curious employees, whose diverse thoughts and perspectives are highly valued. Arvinas employees embrace the freedom to pursue innovation, think creatively, and give back. They are driven by the company’s values and mission – to improve the lives of patients with serious diseases by pioneering therapies created with our revolutionary PROTAC protein degradation platform. We’re really excited about the work we’re doing inside and outside of Arvinas, and think you will be, too. But don’t just take our word for it –&nbsp;<a href="https://www.arvinas.com/join-us/">learn more about life at Arvinas and what employees have to say</a>.
Arvinas is headquartered in New Haven, Connecticut. For more information about Arvinas, visit <a href="https://nam12.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.globenewswire.com%2FTracker%3Fdata%3DQTKP1AChye8S7dRwe0FGYwu0ASE--zITIauazocCQUpe2DkUxcUj5W1I4cfB1VdO8PVJmxOiRI8fyIuEslojKSYyZln8pFoYlnnKoisk18u9wY2KWfO5I8tIoKJ1I5oE9TvQw90ujFNcTXtCBoST4rpCnVmyq_bQjbPCaKcDaeva1DhxPsgUbV2x6kh95OXKS4Gzr_d4OLByl8cWsn8MhqE9J7_azRrETUVqYiTTFhCgB4a_TxurJh4g42YBTrjGNj5b08Gj2rR6kArTke1SRg%3D%3D&amp;data=05%7C02%7CDeborah.Kroeger%40arvinas.com%7C202d1e871fda43d5045d08de94ba5987%7Cbcd7979d52a541139e043a50e328956b%7C0%7C0%7C639111725259238508%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&amp;sdata=CV6pBG4YBDEBDaNjZrc69b%2BEnz9plvW4y5PQM%2BNP%2F8A%3D&amp;reserved=0">www.arvinas.com</a>&nbsp;and connect on&nbsp;<a href="https://nam12.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.globenewswire.com%2FTracker%3Fdata%3DglMJKSe9q3igeILqGtZIMplADQLJW3KEXczhywHiVeby7c0pVYthpfc-pK_BgSuqnX_gDh7n_3mHOWfSLPE20AteuBJWn9aWGZWRFM4rfcAb-NBi2v5sBccEovscinrRtuoXoFltA1Q7gNq80tKS4WMVUK_CtkxY1Z1bdw8R0DYgX8tvkNt4Orgec4qO3HjYEcqK0ixIw1xTA4NYidJZSZzDG3q_5J2nspXMNm8w9CAQnsPEHoBjYvs6n69om10LoaJANq5xTb9mYe9JIe8mow%3D%3D&amp;data=05%7C02%7CDeborah.Kroeger%40arvinas.com%7C202d1e871fda43d5045d08de94ba5987%7Cbcd7979d52a541139e043a50e328956b%7C0%7C0%7C639111725259312103%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&amp;sdata=u1qLPtd8mALZ3hwHp8HgNUOMb1kjvAtKZvQsZcuqRXU%3D&amp;reserved=0">LinkedIn</a>&nbsp;and&nbsp;<a href="https://nam12.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.globenewswire.com%2FTracker%3Fdata%3DcTxzc5WqbjgBt1cspxvM1BXKzup1UAy5xeS_92lpGW2vWgtY54G3VVxHA6k6iXTQj5aSSq5_aS_Av4nL6t4t5bDzKSTJau6_Yh3qpNbWa0IOyq4gIah4e2M5MjucC2BQ7FESacgel3ANUhjAf1ruJPbsJn_rKY6pAq8SKO2iw7okmGshi2dhTcZCytNSTEAWtBjIlMaEwKfVrvgnwo2smg%3D%3D&amp;data=05%7C02%7CDeborah.Kroeger%40arvinas.com%7C202d1e871fda43d5045d08de94ba5987%7Cbcd7979d52a541139e043a50e328956b%7C0%7C0%7C639111725259384931%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&amp;sdata=ELhoRnt0fYjwx9uM0U2kzUuzyfU8ap%2BE8hW9EFazX54%3D&amp;reserved=0">X</a>.
&nbsp;
Position Summary&nbsp;
The Vice President and Head of Neuroscience is responsible for enterprise leadership of all aspects of driving the neuroscience portfolio. This includes managing exploratory new target selection, generation of in vitro and in vivo data used to develop pharmacokinetic / pharmacodynamic relationships, and the identification of translational biomarkers to support optimization and clinical development of PROTAC degrader molecules for severe neurologic disorders.&nbsp;
This position reports to the Chief Scientific Officer and will be located at our headquarters in New Haven, CT.
&nbsp;Principal Responsibilities
Key responsibilities of this role include, but are not limited to:
<ul>
<li>Leads the neuroscience organization with bold new vision, clarity, purpose, and scientific excellence, fostering a culture of innovation and collaboration while advancing and prioritizing high-impact programs from discovery through clinical development.</li>
<li>Builds, leads and inspires a high-performing team through mentorship and development of leadership, scientific and technical capabilities.</li>
<li>Enables the team to identify, develop, and apply relevant preclinical in vivo models to support target validation, lead identification, and optimization. Uses a deep understanding of disease and target biology to guide key scientific decisions and oversees the development of robust target engagement, pathway biology, and biomarker assays that support preclinical pharmacology and translational research.</li>
<li>Provides strategic oversight for the design, execution, and interpretation of preclinical pharmacology studies to characterize compound activity, establish pharmacokinetic/pharmacodynamic (PK/PD) relationships, and guide candidate optimization. Leverages study outcomes to support translational strategies, inform human dose projections, and advance programs toward clinical development.</li>
<li>Collaborates cross-functionally with Research, Translational Sciences, Clinical Development, Regulatory, and Biometrics leaders to define and execute integrated development strategies across the neuroscience portfolio.</li>
<li>Establishes and leads strategic collaborations with biopharma partners, key scientific investigators, contract research organizations, academic institutions, and external partners to advance translational neuroscience, induced pluripotent stem cell models, biomarker assay capabilities, including assay transfer, method development, qualification, validation, and clinical implementation.</li>
<li>Provides scientific leadership and strategic oversight for the generation, interpretation, and communication of preclinical pharmacology and translational data to support regulatory submissions, including INDs, CTAs, Investigator Brochures, clinical study protocols, study reports, and laboratory manuals.</li>
<li>Collaborates across research and development functions to define program strategy, drive execution, and accelerate pipeline progression, leveraging high-quality in vivo pharmacology, biomarker, and translational data to support critical development and portfolio decisions.</li>
<li>Provides leadership, mentorship, and talent development across the neuroscience organization, fostering a culture of collaboration, trust, accountability, and scientific excellence that enables teams to achieve their highest potential.</li>
</ul>
Qualifications
<ul>
<li>Established scientific reputation in neuroscience and neurodegenerative disease research, with extensive experience applying quantitative and statistical approaches to evaluate disease-relevant in vivo models and translational biomarker endpoints. Recognized through influential publications, scientific leadership, and a strong network of academic, clinical, and industry collaborators.</li>
<li>Recognized leader with a strong track record of initiating and cultivating high-value collaborations with academic thought leaders, research consortia, CROs, foundations, and patient advocacy groups to drive scientific innovation, translational research, and therapeutic development in neurodegenerative diseases.</li>
<li>Leader with extensive experience building and leading multidisciplinary teams focused on preclinical pharmacology and translational medicine, leveraging disease-relevant models and human biomarker data to drive critical development decisions and advance neuroscience programs from discovery through clinical proof of concept.</li>
<li>Examples of contributions to exploratory neuroscience target selection and demonstrated ability to use in vitro pharmacology data to drive program decisions and portfolio build.&nbsp;</li>
<li>Clear track record of authoring relevant sections of IND/ CTA documents and contributions to clinical protocol design.&nbsp;</li>
<li>Proven track record of building, mentoring, and motivating multidisciplinary teams to deliver critical program and portfolio decisions. Demonstrated expertise in neuroscience target discovery and evaluation, leveraging in vitro pharmacology, disease biology, and translational insights to shape development strategies, prioritize assets, and advance innovative therapeutic portfolios.</li>
</ul>
<ul>
<li>Exceptional communicator and proactive leader with a strong work ethic, demonstrated ability to influence and collaborate across all levels of the organization and the broader neuroscience community, and a proven track record of driving accountability and results. Recognized through scientific publications, presentations, inventions, regulatory contributions, and leadership in advancing portfolio and development objectives.</li>
<li>Must be authorized to work in the United States without current or future employer-sponsored visa sponsorship. This leadership role operates at the main office of Arvinas 3+ days/ week and in a hybrid work environment, requiring regular engagement across office, laboratory, and remote settings. The successful candidate must be able to effectively lead teams, collaborate across functions, communicate complex scientific concepts, and influence internal and external stakeholders. The role requires the ability, with or without reasonable accommodation, to perform essential job functions, including participation in laboratory and office activities, use of computer and communication technologies, engagement in scientific and strategic discussions, and occasional travel. Compliance with laboratory safety procedures, including the use of personal protective equipment (PPE) and work around biological and hazardous materials, may be required.</li>
</ul>
&nbsp;
&nbsp;
Education&nbsp;
<ul>
<li>Ph.D., with 15+ years of industry/ biotech leadership experience in neurobiology and pharmacology with clear contributions to clinical candidates.</li>
</ul>
Arvinas is proud to offer a competitive package of base and incentive compensation as well as a comprehensive benefits program designed to support the health, wellness and financial security of our employees and their families. Benefits include group medical, vision and dental coverage, group and supplemental life insurance, and much more. To learn more about Arvinas, please visit <a href="http://www.arvinas.com">www.arvinas.com</a> 
Arvinas is an equal opportunity employer. All qualified applicants will be considered for employment without regard to race, color, religion, sex, sexual orientation, gender identify, national origin, disability or protected veteran status.&nbsp;
&nbsp;
&nbsp;

Get a job referral to Arvinas

Description

Jobs· 10 open

About

Financials

Referrals

Your career is worth investing in.

Get unlimited referrals with Premium.